carbostyril has been researched along with Pulmonary Disease, Chronic Obstructive in 295 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 12 (4.07) | 29.6817 |
| 2010's | 258 (87.46) | 24.3611 |
| 2020's | 25 (8.47) | 2.80 |
| Authors | Studies |
|---|---|
| Kato, C; Nakamura, N; Sasajima, T; Yoshisue, H | 1 |
| Bougard, N; Louis, G; Louis, R; Pétré, B; Schleich, F | 1 |
| Chan, MC; Chen, NH; Cheng, SL; Hsieh, MJ; Hsu, WH; Kuo, PH; Lin, MS; Liu, CL; Liu, SF; Tao, CW; Tsai, YH; Wei, YF; Wu, YK; Yang, TM | 1 |
| Aranda-Chávez, A; Flores-Trujillo, F; Guzmán-Bouilloud, NE; Hernández-Zenteno, RJ; Mayar-Maya, ME; Pérez Lara-Albisua, JL; Ramírez-Venegas, A; Sansores, RH; Velázquez-Uncal, M | 1 |
| Singh, D | 2 |
| Ascuntar, C; Aviles, S; Benavides-Cordoba, V; Mosquera, R; Orozco, L; Rivera, J | 1 |
| Alcazar, B; Barrecheguren, M; Kostikas, K; Mezzi, K; Miravitlles, M; Shen, S; Soler-Cataluña, JJ; Wedzicha, JA | 1 |
| Huang, J; Huang, Z; Pei, Q; Yang, G; Yang, Q; Yang, S; Yang, X; Zhang, X; Zou, C | 1 |
| Banerji, D; Frent, SM; Gupta, P; Kostikas, K; Mackay, AJ; Olsson, P; Patalano, F; Pfister, P; Roche, N; Wedzicha, JA | 1 |
| Baidoo, C; Castro-Santamaria, R; Crawford, C; Crim, C; Emmett, A; Gotfried, M; Spangenthal, S; Watkins, M | 1 |
| Danyliv, A; Gutzwiller, FS; Lakhotia, B; Mahon, R; Nikolaev, I; Thokala, P | 1 |
| Aisanov, ZR; Avdeev, SN; Beeh, KM; Belevsky, AS; Ignatova, GL; Kostikas, K; Leshchenko, IV; Ovcharenko, SI; Shmelev, EI; Sinopal'nikov, AI; Titova, ON; Vizel, AA; Zyryanov, SK | 1 |
| Finnegan, R; O'Grady, E; Ryan, S; Smyth, A; Williamson, M | 1 |
| Beier, J; Friedrich, FW; Plate, T | 1 |
| Carpaij, OA; Kerstjens, HAM; Niemeijer, A; Seigers, D; van Geffen, WH; Vonk, JM; Westbroek, LF | 1 |
| Danahay, H; Dransfield, MT; Gleason, S; Gosling, M; Grant, SS; Haque, N; Hayes, KA; Jones, I; Kulmatycki, K; Rowe, SM; Rowlands, DJ; Yates, DP | 1 |
| Dias, S; Fortescue, R; Janjua, S; Mathioudakis, AG; Sharif, S; Threapleton, CJ; Walker, RA | 1 |
| Antonelli, PJ; Hincapie-Castillo, JM; Tran, PT; Winterstein, AG | 1 |
| Cheng, SH; Hsu, YJ; Huang, YL; Lai, JH; Lin, CW; Liou, JT; Pan, HY; Tsai, CL; Wang, MT | 1 |
| Bartels, C; Jain, M; Tillmann, HC; Vaidya, S; Yu, J | 1 |
| Aritake, H; Gamo, S; Ichinose, M; Kazama, I; Murakami, K; Nara, M; Sugiura, H; Tamada, T | 1 |
| Adams, SG; Peters, JI | 1 |
| Elzinga, CRS; Han, B; Maarsingh, H; Meurs, H; Oldenburger, A; Schmidt, M; Sopi, RB; Timens, W; Zuidhof, AB | 1 |
| Gallo, O; Mangia, PP; Pradelli, L; Ritrovato, D | 1 |
| Abo, M; Hara, J; Kasahara, K; Kimura, H; Nishikawa, S; Ogawa, N; Ohkura, N; Sone, T; Tambo, Y; Tanaka, R; Watanabe, S | 1 |
| Corhay, JL | 1 |
| Ficker, JH; Rabe, KF; Welte, T | 1 |
| Cao, W; Decuypère, L; Devouassoux, G; Girodet, PO; Jasnot, JY; Le Gros, V | 1 |
| Banerji, D; Fogel, R; Fucile, S; Kostikas, K; Mezzi, K; Shen, S; Tsiligianni, I | 1 |
| Jung, KS; Kim, CJ; Kim, S; Kim, YS; Lee, YC; Lim, SY; Oh, YM; Park, JW; Park, MJ; Shim, JJ; Yoo, CG; Yoo, KH; Yoon, HK | 1 |
| Aalamian-Mattheis, M; Castellani, W; Clemens, A; Gaga, M; Greulich, T; Kostikas, K; Lane, S; Marin, JM; Ninane, V; Nunez, X; Patalano, F; Vogelmeier, CF | 1 |
| Cazzola, M; Rogliani, P | 1 |
| Buhl, R; Criée, CP; Kardos, P; Lossi, NS; Vogelmeier, CF; Worth, H | 1 |
| Ayers, T; Banerji, D; Ferguson, GT; Fogel, R; Goodin, T; Kerwin, E; Maitra, S; Sanjar, S; Sen, B; Yadao, A | 1 |
| Banerji, D; Fogel, R; Patalano, F | 1 |
| Physicians From Medical Centers In Poland, GO; Płusa, T | 1 |
| Fujimoto, K; Kitaguchi, Y; Ura, M; Yamazaki, H | 1 |
| Hida, N; Hizawa, N; Nakaizumi, T; Satoh, H; Terashima, H; Yamada, H | 1 |
| Deas, SD; Huprikar, N | 1 |
| Bjermer, L; Costa-Scharplatz, M; Gutzwiller, FS; Keininger, DL; Lisspers, K; Mahon, R; Olsson, P; Roche, N; van Boven, JFM | 1 |
| Kang, J; Kim, EK; Kim, JH; Kim, KT; Kim, TH; Kim, WJ; Lee, JH; Lee, JS; Oh, YM; Yoo, KH | 1 |
| Cohuet, G; Corradi, M; Fabbri, L; Guasconi, A; Montagna, I; Papi, A; Petruzzelli, S; Prunier, H; Roche, N; Scuri, M; Singh, D; Vestbo, J; Vezzoli, S | 1 |
| Burke, C; Chow, WL; Guruprasad, B; Tee, A | 1 |
| Aalamian-Mattheis, M; Clemens, A; Fogel, R; Kostikas, K; Nunez, X; Pagano, VA; Patalano, F | 1 |
| Aftab, B; Amir, N; Fayyaz, A; Hanif, M; Ijaz, H; Mustafa, MI; Qureshi, J; Rasul, A | 1 |
| Balis, E; Metaxas, EI | 1 |
| Banerji, D; Chapman, KR; Fogel, R; Frent, SM; Goyal, P; Guerin, T; Hurst, JR; Kostikas, K; Larbig, M; Patalano, F; Pfister, P; Wedzicha, JA | 1 |
| Abdulmwli, M; Anderson, D; Demir, E; Habas, K; Jacob, BK; Najafzadeh, M | 1 |
| Iwakura, M; Satake, M; Sato, S; Shioya, T; Takahashi, H; Terui, Y; Uemura, S | 1 |
| Tashkin, DP | 3 |
| Anzueto, AR; Banerji, D; Fogel, R; Kostikas, K; Larbig, M; Mezzi, K; Patalano, F; Shen, S; Wedzicha, JA | 1 |
| Banerji, D; Chapman, KR; Fogel, R; Frent, SM; Gutzwiller, FS; Kostikas, K; Larbig, M; Mackay, A; Patalano, F; Shen, S; Wedzicha, JA | 1 |
| Ashmawi, S; Backer, A; Diaz, DV; Frith, PA; Gurgun, A; Hamann, AM; Hristoskova, S; Kostikas, K; Krishnamurthy, S; Olsson, P; Pilipovic, V | 1 |
| Lan, G; Shi, G | 1 |
| Chapman, KR; Fogel, RB; Hurst, JR; Kostikas, K; Pfister, P; Wedzicha, JA | 1 |
| Kasak, V; Klimes, J; Skoupa, J; Valena, T | 1 |
| Fogel, R; Fucile, S; Goyal, P; Jenkins, C; Kostikas, K; Mezzi, K; Shen, S; Singh, D; Tsiligianni, I; Wedzicha, JA | 1 |
| Bentivenga, C; Berardi, E; Borghi, C; Bui, V; Cicero, AF; Cosentino, ER; Esposti, DD; Landolfo, M; Miceli, R; Spinardi, L | 1 |
| Watz, H | 1 |
| Lad, R; Rhee, CK; Yoshisue, H | 1 |
| Dorman, J; Kelly, K; Lacey, S; McGrath, K; Molony, D; O'Doherty, B; Schmid, S; Sullivan, S; Whelan, S | 1 |
| Abadelah, M; Chrystyn, H; Larhrib, H | 1 |
| Bowling, A; Goodin, T; Ozol-Godfrey, A; Price, B; Sanjar, S; Sharma, S; Tashkin, DP | 1 |
| Chu, Y; Fu, H; Gou, X; Li, J; Lin, J; Pan, W; Wang, X; Yan, C; Yuan, Y; Yue, B; Zhao, K; Zhou, Y | 1 |
| Baggen, S; Chan, R; Locantore, N; Ludwig-Sengpiel, A; Riley, JH; Wielders, PL | 1 |
| Feldman, GJ | 1 |
| Buhl, R; Lawrence, D; Mahler, DA; McBryan, D | 1 |
| Cazzola, M; Matera, MG; Picciolo, S; Proietto, A; Rogliani, P; Ruggeri, P; Segreti, A | 1 |
| Connolly, MJ; Hanania, NA; Yohannes, AM | 1 |
| Ambery, C; Norris, V | 1 |
| Ananthapavan, J; Asukai, Y; Keyzor, I; Malcolm, B; Price, D; Radwan, A | 1 |
| Ambery, C; Bateman, ED; Kornmann, O; Norris, V | 1 |
| Calzetta, L; Cazzola, M; Fiori, E; Rogliani, P; Sabatini, M; Segreti, A; Segreti, V | 1 |
| Dai, L; Han, J; Zhong, N | 1 |
| Bellido, I; Carrascosa, MF; Lucena, MI; Salcines-Caviedes, JR | 1 |
| Calero, C; Lopez-Campos, JL; Quintana-Gallego, E | 1 |
| Alagappan, VK; Banerji, D; Chapman, KR; Chen, H; Dahl, R; Kho, P; Mehta, R; Rudolf, M | 1 |
| Schachter, EN | 1 |
| Polese, G; Rossi, A | 1 |
| Chung, VC; Hui, DS; Ma, PH; Tam, WW; Tang, JL | 1 |
| Thompson, H | 1 |
| Cazzola, M; Lopez-Campos, JL; Puente-Maestu, L | 1 |
| Incorvaia, C; Montagni, M; Olivieri, E; Riario-Sforza, GG; Ridolo, E | 1 |
| Baldwin, M; Buckley, F; Capkun-Niggli, G; Cope, S; Donohue, JF; Ellis, A; Jansen, JP; Jones, P; Kraemer, M | 1 |
| Alagappan, VK; Banerji, D; Chen, H; Dahl, R; Jadayel, D | 1 |
| Alagappan, VK; Banerji, D; Chen, H; D'Urzo, A; Decramer, M; Gallagher, N; Kulich, K; Mahler, DA; White, T; Worth, H | 1 |
| Cazzola, M; Ciaprini, C; Ora, J; Rogliani, P; Senis, L; Stirpe, E | 1 |
| Antoniu, S; Râjnoveanu, RM; Ulmeanu, R | 1 |
| Calzetta, L; Cazzola, M; Matera, MG; Page, CP | 1 |
| Alagappan, VK; Banerji, D; Bateman, ED; Chen, H; D'Andrea, P; Pallante, J; Vogelmeier, CF | 1 |
| Singh, MP | 1 |
| Archontogeorgis, K; Bouros, D; Nena, E; Steiropoulos, P | 1 |
| Chen, P; Han, X; Henley, M; Kramer, B; Wang, C; Wu, C; Yan, X; Yang, W; Yao, W; Zhong, N | 1 |
| Komaroff, AL | 1 |
| Han, MK | 1 |
| Arrasate, C; Banerji, D; Chen, H; D'Andrea, P; Decramer, M; Ficker, JH; Niewoehner, DE; Sandström, T; Taylor, AF; Wedzicha, JA | 2 |
| Yaqub, F | 1 |
| Van Meerhaeghe, A; Vanhaeverbeek, M | 1 |
| Martinez, FJ | 1 |
| Cameron, R; Chapman, KR; Dahl, R; Decramer, ML; Devouassoux, G; Frith, P; Fritscher, C; Lawrence, D; McBryan, D; Shoaib, M; Young, D | 1 |
| Hanada, S; Muraki, M; Ohno, T; Sawaguchi, H; Tohda, Y; Wada, S | 1 |
| Baker, WR; Cui, ZH; Kim, M; Patel, L; Phillips, GB; Salmon, M; Sorensen, EA; Tannheimer, SL; Wright, CD | 1 |
| Banerji, D; Beeh, KM; Beier, J; D'Andrea, P; Henley, M; Jadayel, D; Korn, S | 1 |
| Plaza, V; Rodrigo, GJ | 1 |
| Aumann, J; Chen, H; Goyal, P; Henley, M; McBryan, D; Vincken, W | 1 |
| Frampton, JE | 1 |
| Hoshino, M; Ohtawa, J | 1 |
| Centanni, S; D'Angelo, E; Di Marco, F; Henchi, S; Pecchiari, M; Radovanovic, D; Santus, P | 1 |
| Ulrik, CS | 3 |
| Anderson, R; Durandt, C; Feldman, C; Steel, HC; Theron, AJ; Tintinger, GR | 1 |
| Banerji, D; Bateman, ED; Mahler, DA; Patalano, F; Vogelmeier, CF; Wedzicha, JA | 1 |
| Jacobsen, JR; Klein, U; Linsell, MS; McKinnell, RM; Moran, EJ; Nodwell, MB; Pfeiffer, JW; Thomas, GR; Yu, C | 1 |
| Incorvaia, C; Montagni, M; Riario-Sforza, E; Riario-Sforza, GG; Ridolo, E | 1 |
| Anzueto, A; Becker, K; Disse, B; Hamilton, A; Roskell, NS | 2 |
| Banerji, D; Buhl, R; Chen, H; D'Andrea, P; Dahl, R; Fogel, R; Schubert-Tennigkeit, A; Wedzicha, JA | 1 |
| Akitsu, K; Hoshino, M; Ohtawa, J | 1 |
| Beeh, KM; Dahl, R; Dederichs, J; Donohue, J; Fülle, HJ; Higgins, M; Molimard, M; Murphy, L; Rennard, S; Young, D | 1 |
| Kianifard, F; LaForce, CF; Siler, TM; Spangenthal, S; Williams, J | 1 |
| Calzetta, L; Cazzola, M; Facciolo, F; Matera, MG; Rogliani, P; Segreti, A | 1 |
| Dekhuijzen, PN; Postma, MJ; van Boven, JF; van der Galiën, R; van der Molen, T; van Raaij, JJ; Vegter, S | 1 |
| Kirsten, A; Krippner, F; Magnussen, H; Vogelmeier, C; Watz, H | 1 |
| Asukai, Y; Costa-Scharplatz, M; Dimova, M; Keininger, D; Mezzi, K; Price, D; Ställberg, B | 1 |
| Altman, P; Bucchioni, E; Cameron, R; del Olmo, R; Lu, C; Papi, A; Quinn, M; Rossi, A; van der Molen, T; Wehbe, L; Young, D | 1 |
| Cazzola, M; Matera, MG; Rogliani, P | 2 |
| Buhl, R; Lawrence, D; Wedzicha, JA; Young, D | 1 |
| Calverley, PM | 2 |
| Inui, N; Kono, M; Matsushima, S; Nakamura, Y; Shirai, T; Suda, T; Toyoshima, M; Yasui, H | 1 |
| Maselli, R; Matera, MG; Pelaia, G | 1 |
| Donohue, JF | 3 |
| Cates, CJ; Dabscheck, EJ; Geake, JB; Wood-Baker, R | 1 |
| Ciabattoni, G; Montuschi, P | 1 |
| Babu, KS; Morjaria, JB; Prakash, A | 1 |
| Chen, Y; Hegde, SS; Hughes, AD; Jasper, JR; Jaw-Tsai, S; Lee, TW; Mammen, M; McNamara, A; Pulido-Rios, MT; Steinfeld, T | 1 |
| Buhl, R; Foerster, K; Gessner, C; Hiltl, S; Korn, S; Schuermann, W; Sieder, C | 1 |
| Baroni, M; Incorvaia, C; Montagni, M; Riario-Sforza, GG; Ridolo, E | 1 |
| Dahl, R; Deslée, G; Donohue, JF; Kerstjens, HA; Kornmann, O; Lawrence, D; Young, D | 1 |
| Kozielski, J | 1 |
| Futami, S; Koba, T; Komuta, K; Minami, S; Nishijima, Y; Ogata, Y; Yamamoto, S | 1 |
| Carriere, KC; Jung, JY; Kim, JS; Kim, MJ; Lim, SY; Oh, YM; Park, HY; Park, J; Park, YB; Sheen, SS; Yoo, KH | 1 |
| Agusti, A; Fabbri, LM | 1 |
| Del Olmo, R; Rossi, A; van der Molen, T; Wehbe, L | 1 |
| Antoniu, SA; Boisteanu, D; Mihaltan, F; Ruxandra, U | 1 |
| Horita, N; Kaneko, T | 1 |
| Banerji, D; Humphries, M; Patalano, F; Thach, C; Wang, C; Wang, L; Zhang, N; Zhong, N; Zhou, X | 1 |
| Altman, P; Buhl, R; Donohue, JF; Kerstjens, HA; Lawrence, D; Mahler, DA | 1 |
| Enomoto, N; Fujisawa, T; Inui, N; Kato, S; Kono, M; Matsushima, S; Nakamura, Y; Suda, T; Toyoshima, M; Yasui, H | 1 |
| Ayers, T; Banerji, D; FowlerTaylor, A; Kerwin, E; Lloyd, M; Mahler, DA; Maitra, S; Patalano, F; Thach, C | 1 |
| Cazzola, M; Poletti, V; Rossi, A; Zanardi, E | 1 |
| Ambery, CL; Chan, R; Ludwig-Sengpiel, A; Riley, JH; Wielders, P | 1 |
| Hubert, M | 2 |
| Cockle, SM; Huisman, EL; Ismaila, AS; Karabis, A; Punekar, YS | 1 |
| Blasi, F; Bussotti, M; Centanni, S; Di Marco, S; Raccanelli, R; Radovanovic, D; Santus, P; Valenti, V | 1 |
| Lee, JS; Oh, YM; Park, J; Rhee, C | 1 |
| Cates, CJ; Farne, HA | 1 |
| Basu Patnaik, S; De Guia, T; El-Sorougi, W; Juvelekian, G; Kuo, HP; Pilipovic, V; Pothirat, C; Yunus, F | 1 |
| Calverley, P; Celli, BR; Chambers, M; Clark, JF; Hawkins, N; Scott, DA; Thompson, JC; Woods, B | 1 |
| Bridgeman, MB; Dalal, KS | 1 |
| Einecke, D | 4 |
| Garcia-Rivero, JL; Miravitlles, M; Montero-Caballero, J; Ortega, F; Ribera, X; Richard, F; Santos, S | 1 |
| Fahy, WA; Galkin, D; Kalberg, C; Newlands, A; O'Dell, D | 1 |
| Bartels, C; Bieth, B; Demin, I; Gautier, A; Graham, G; Sechaud, R; Tillmann, HC | 1 |
| Anzueto, A; Halpin, DM; Metzdorf, N; Pieper, MP; Richard, F; Vogelmeier, C | 1 |
| Ayers, RT; Banerji, D; Chapman, KR; Fogel, R; Patalano, F; Roche, N; Thach, C; Vestbo, J; Vogelmeier, CF; Wedzicha, JA | 1 |
| Acosta, EP; Dransfield, MT; Hathorne, H; Liu, B; Raju, SV; Reeves, G; Rowe, SM; Solomon, GM | 1 |
| Banerjee, R; D'Andrea, P; Eckert, JH; Gifford, AH; Jessop, N; Mahler, DA; Mota, F; Satti, A | 1 |
| Kuwahira, I | 1 |
| Baier, M; Kirsten, A; Mailänder, C; Watz, H | 1 |
| Fernández-Villar, A; Leiro-Fernández, V; Priegue Carrera, A | 1 |
| Astbury, C; Beier, J; de Miquel, G; Jimenez, E; Massana, E; Pujol, H; Ruiz, S; Seoane, B | 1 |
| Carrasco, J; Chehab, S; Gruenberger, JB; Keininger, DL; Molimard, M; Pitotti, C; Price, D; Reza Maleki-Yazdi, M; Sauvage, E | 1 |
| Banerji, D; Vogelmeier, CF; Wedzicha, JA | 1 |
| Suissa, S | 1 |
| Franssen, FM; Vanfleteren, LE; Wouters, EF | 1 |
| Contoli, M; Morelli, P; Papi, A | 1 |
| Ito, YM; Kanda, R; Konno, S; Makita, H; Nakano, Y; Nishimura, M; Ogawa, E; Seto, R; Shimizu, K; Suzuki, M | 1 |
| Bader, G; Banerji, D; Fogel, R; Humphries, MJ; Mezzi, K; Patalano, F; Vogelmeier, C; Zhong, N | 1 |
| Azzola, A; Brutsche, M; Clemens, A; Domenighetti, G; Fitting, JW; Frey, JG; Geiser, T; Kostikas, K; Salomon, J; Schmidt, U; Sigrist, T; Stolz, D; Turk, AJ; Wild, C | 1 |
| Bourdeix, I; Burgel, PR; Decuypère, L; Deslée, G; Le Gros, V; Perez, T | 1 |
| Hwang, YI; Jung, JY; Jung, KS; Kim, S; Kim, TH; Lee, JH; Lee, SW; Park, HY; Park, JW; Rhee, CK | 1 |
| Kadoya, K; Kaga, N; Liu, X; Nagahama, KY; Namba, Y; Orimo, A; Taka, H; Takahashi, K; Togo, S; Tulafu, M | 1 |
| Greos, L; Higgins, M; LaForce, C; Orevillo, CJ; Owen, R; Pearlman, DS | 1 |
| Bauwens, O; Dong, F; Firth, R; Higgins, M; Ninane, V; Owen, R; Van de Maele, B | 1 |
| Beeh, KM; Beier, J; Brookman, L; Hmissi, A; Pascoe, S; Peachey, G | 1 |
| Beeh, KM; Beier, J | 2 |
| Barnes, PJ; Higgins, M; Iqbal, A; Kramer, B; Lawrence, D; Magnussen, H; Pocock, SJ | 1 |
| Feldman, G; Higgins, M; Jack, D; Kramer, B; Owen, R; Piggott, S; Prasad, N; Siler, T | 1 |
| Chazan, R | 1 |
| Donohue, JF; Fogarty, C; Higgins, M; Iqbal, A; Kramer, B; Lötvall, J; Mahler, DA; Owen, R; Swales, J; Worth, H; Yorgancioglu, A | 1 |
| Cazzola, M; Matera, MG; Proietto, A | 1 |
| Bleasdale, P; Buhl, R; Chung, KF; Dahl, R; Higgins, M; Jack, D; Kramer, B; Magnussen, H; Nonikov, V; Owen, R | 1 |
| Gillissen, A; Häussermann, A | 1 |
| Emery, C; Fukuchi, Y; Higgins, M; Hosoe, M; Kato, M; Kramer, B; Makita, H; Uemura, K | 1 |
| Aumann, J; de Teresa Parreño, L; Higgins, M; Iqbal, A; Kramer, B; Laforce, C; Owen, R; Young, D | 1 |
| Centanni, S; Dahl, R; Dogra, A; Kornmann, O; Kramer, B; Lassen, C; Owen, R | 1 |
| Dalvi, M; Dederichs, J; Fiebich, K; Mueller, S; Pavkov, R; Pignatelli, G; Rietveld, I; Singh, D; Stowasser, F; Walter, B; Ziegler, D | 1 |
| Henley, M; Higgins, M; Jack, D; Jadayel, D; Kramer, B; Magnussen, H; Verkindre, C; Woessner, R | 1 |
| Amos, C; Balint, B; Higgins, M; Kramer, B; Owen, R; Watz, H | 1 |
| Higgins, M; Jack, D; Kramer, B; Owen, R; Piggott, S; Ramos-Barbon, D; Vogelmeier, C | 1 |
| Buhl, R; Dolker, M; Jones, F; Laforce, C; Martin, C; Overend, T; van Noord, JA | 1 |
| Amor-Carro, O; Brienza, NS; Ramos-Barbón, D | 1 |
| Moen, MD | 1 |
| Dolker, M; Fabbri, LM; Horton, R; Martin, C; Overend, T; Van de Maele, B | 1 |
| Hosoe, M; Kramer, B; Lawrence, D; Matsushima, S; Woessner, R | 1 |
| Chung, KF; Felser, JM; Hu, H; Rueegg, P; Worth, H | 1 |
| Brookman, L; Hmissi, A; Kaiser, G; Pascoe, S; Perry, S; Pleskow, W; Reynolds, C | 1 |
| Chung, KF; Hui, CK | 1 |
| Chapman, KR; Dogra, A; Kramer, B; Lassen, C; Owen, R; Rennard, SI | 1 |
| Amos, C; Atis, S; Kerwin, E; Korn, S; Lassen, C; Owen, R | 1 |
| Gale, R; Jones, PW; Kramer, B; Mahler, DA; Owen, R | 1 |
| Rochat, T | 1 |
| Casaburi, R; Kramer, B; Lawrence, D; O'Donnell, DE; Puente-Maestu, L; Swales, J; Vincken, W | 1 |
| Chazan, RC | 1 |
| Kramer, B; Lawrence, D; Looby, M; Morris, D; Renard, D; Stanski, DR | 1 |
| Płusa, T | 1 |
| Amos, C; Buhl, R; Disdier, C; Dunn, LJ; Henley, M; Kramer, B; Lassen, C | 1 |
| Capkun-Niggli, G; Cope, S; Gale, R; Jansen, JP; Jardim, JR | 1 |
| Kramer, B; LaForce, C; Magnussen, H; Owen, R; Vogelmeier, C | 1 |
| Nie, B; Wang, J; Xiong, W; Xu, Y | 1 |
| Chapman, KR; Dalvi, M; Dederichs, J; Fogarty, CM; Jadayel, D; Kramer, B; Lassen, C; Peckitt, C | 1 |
| Capkun-Niggli, G; Gale, R; Houghton, K; Jones, P; Stull, DE; Wiklund, I | 1 |
| Asukai, Y; Gale, R; Gantner, T; Gray, A; Lloyd, A; Mungapen, L; Neidhardt, K; Peters, L; Price, D | 1 |
| Barnes, N; Jones, PW; Kramer, B; Lawrence, D; Vogelmeier, C | 1 |
| Beeh, KM; Drollmann, AF; Khindri, S; Wagner, F | 1 |
| Donohue, JF; Martinez, FJ | 1 |
| Corhay, JL; Louis, R | 1 |
| Bleecker, ER; Kramer, B; Owen, R; Siler, T | 1 |
| Donohue, JF; Kornmann, O; Kramer, B; Lassen, C; Lawrence, D; Singh, D | 1 |
| Brusasco, V; Cazzola, M; Centanni, S; Cerveri, I; Foresi, A; Gulotta, C; Rossi, A | 1 |
| Fukuchi, Y; Hang, LW; Hosoe, M; Ichinose, M; Kinoshita, M; Kramer, B; Lee, SH; Okino, N; Prasad, N | 1 |
| Hurwitz, C; Leroy, E; Lewitzky, S; Li, Y; Paulding, CA; Rodman, D; Trifilieff, A; Yelensky, R | 1 |
| Chowdhury, BA; Durmowicz, AG; Liu, D; Michele, TM; Rosebraugh, CJ; Seymour, SM | 1 |
| Gotfried, MH; Kerwin, EM; Kramer, B; Lassen, C; Lawrence, D | 2 |
| Donohue, JF; Jones, PW; Lassen, C; Nedelman, J; Pascoe, S; Pinault, G | 1 |
| Duh, D; Tanret, I | 1 |
| Fabbri, LM | 1 |
| McKeage, K | 1 |
| Neffen, H; Rodrigo, GJ | 1 |
| Chapman, KR; Ribeiro, M | 1 |
| Bouros, D; Nena, E; Papanas, N; Steiropoulos, P | 1 |
| Franks, AS; Helmer, RS; McMillen, JC; Ray, SM; Treadway, SA | 1 |
| Cates, CJ; Karner, C | 1 |
| Bateman, ED; D'Urzo, A; Kramer, B; Lassen, C; Mahler, DA; Ozkan, SA; Peckitt, C; White, T | 1 |
| Chowdhury, BA; Gobburu, JV; Lee, JY; Michele, T; Wang, Y | 1 |
| Bergman, G; Capkun-Niggli, G; Cope, S; Gale, R; Jansen, JP; Lassen, C; Ouwens, MJ; Owen, R | 1 |
| Cope, S; Jansen, JP; Williams, J; Zhang, J | 1 |
| Cheung, SH; Hayter, AJ; Kwong, KS; Wen, MJ | 1 |
| Kitawaki, T; Matsushima, S; Suzuki, K; Uchiyama, M; Yoshiki, M | 1 |
| Lindenauer, PK; Pekow, PS; Rothberg, MB; Shieh, MS; Stefan, MS | 1 |
| Chyczewska, E; Minarowski, L; Mroz, RM | 1 |
| Capkun-Niggli, G; Cope, S; Jansen, JP; Kraemer, M; Zhang, J | 1 |
| Chong, J; Karner, C; Poole, P | 1 |
| Derendorf, H | 1 |
| Looby, M; Morris, D; Renard, D; Stanski, D; Wright, A | 1 |
| Decramer, M; Lawrence, D; McBryan, D; Rossi, A | 1 |
| Fukuchi, Y; Hang, LW; Ichinose, M; Kinoshita, M; Kitawaki, T; Kramer, B; Lawrence, D; Lee, SH; Okino, N; Prasad, N; To, Y | 1 |
| Lundquist, LM; Metzger, NL | 1 |
| Cazzola, M; Matera, MG; Ora, J; Puxeddu, E; Rogliani, P; Segreti, A; Stirpe, E | 1 |
| Chapman, KR | 1 |
| Dahl, R; Decramer, M; Korn, S; Kornmann, O; Lawrence, D; McBryan, D | 1 |
| Gabazza, EC; Hataji, O; Ito, K; Naito, M; Taguchi, O; Watanabe, F | 1 |
| Kerwin, EM; Williams, J | 1 |
| Jiang, FM; Li, CT; Liang, ZA; Luo, J; Wang, RC; Zheng, QL | 1 |
| Decramer, ML; Hanania, NA; Lötvall, JO; Yawn, BP | 1 |
| Currie, GP | 1 |
| Bao, W; Beier, J; Chanez, P; Higgins, M; Jack, D; Martinot, JB; Schreurs, AJ; Tkácová, R | 1 |
| Dimopoulos, G; Falagas, ME; Korbila, IP; Manta, K; Siempos, II | 1 |
| Cazzola, M; Matera, MG | 1 |
| Fuchikami, J; Takahashi, M; Takeuchi, Y | 1 |
| Bantje, T; Centanni, S; Chanez, P; Chuchalin, A; D'Urzo, A; Higgins, M; Jack, D; Kornmann, O; Owen, R; Perry, S; Rennard, S | 1 |
| Cantoni, V; Catalanotti, P; Cazzola, M; Fici, F; Matera, MG; Polverino, M; Rossi, F; Sarlo, F; Tufano, MA | 1 |
| Cantoni, V; Melani, AS; Pirrelli, M; Sarlo, F | 1 |
82 review(s) available for carbostyril and Pulmonary Disease, Chronic Obstructive
| Article | Year |
|---|---|
Effect of 12-week of aerobic exercise on hormones and lipid profile status in adolescent girls with polycystic ovary syndrome: A study during COVID-19.
Topics: Actin Cytoskeleton; Actins; Adaptor Proteins, Signal Transducing; Adenocarcinoma; Adenosine Triphosphate; Adsorption; Adult; Africa, Eastern; Aged; Air Pollutants; Air Pollution; Air Pollution, Indoor; Alcohol Drinking; Allergens; Alzheimer Disease; Amyotrophic Lateral Sclerosis; Animals; Anti-Bacterial Agents; Antibodies; Antibodies, Immobilized; Antigen Presentation; Antigens, CD; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Apoptosis; Aptamers, Nucleotide; Asthma; Asthma, Exercise-Induced; Atrophy; Autophagy; Azoospermia; Bacillus cereus; Bacterial Infections; Beclin-1; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Biofouling; Biological Monitoring; Biomarkers; Biomarkers, Tumor; Biosensing Techniques; Blastocyst; Bone Neoplasms; Bone Regeneration; Bronchoconstriction; Burkitt Lymphoma; C9orf72 Protein; Campylobacter; Campylobacter Infections; Campylobacter jejuni; Carcinogenesis; Carcinoma, Hepatocellular; Carcinoma, Pancreatic Ductal; Carcinoma, Squamous Cell; Cardiomyopathies; Caregivers; Carmine; Case-Control Studies; Catalysis; Cattle; Cause of Death; CCAAT-Enhancer-Binding Protein-alpha; CD8-Positive T-Lymphocytes; Cefepime; Cell Differentiation; Cell Line, Tumor; Cell Nucleus; Cell Transdifferentiation; Chelating Agents; Chemical and Drug Induced Liver Injury, Chronic; Chemoradiotherapy, Adjuvant; Child; Child, Preschool; China; Chlorquinaldol; Cholangiocarcinoma; Cholera; Chromatin; Clinical Trials as Topic; Cognitive Dysfunction; Cohort Studies; Colonic Neoplasms; Colorectal Neoplasms; Colorimetry; Cooking; Coordination Complexes; COVID-19; Creatinine; CRISPR-Cas Systems; Critical Care; Critical Illness; Cross-Sectional Studies; Cryopreservation; Cryoprotective Agents; Cysteine; Cytokines; Device Removal; Diet; Diet, High-Fat; Diet, Mediterranean; Dietary Supplements; Dimethyl Sulfoxide; Dipeptides; Disease Models, Animal; Dithiothreitol; DNA; DNA Repeat Expansion; DNA, Bacterial; DNA, Complementary; Dopamine; Electrochemical Techniques; Electrodes; Endocannabinoids; Environmental Exposure; Environmental Monitoring; Environmental Pollutants; Enzyme-Linked Immunosorbent Assay; Erlotinib Hydrochloride; Escherichia coli; Escherichia coli O157; Esophageal Neoplasms; Esophagitis, Peptic; Ethylene Glycol; Europium; Exanthema; Fallopian Tubes; Feces; Female; Fertilization in Vitro; Fluoresceins; Fluorescent Dyes; Follicle Stimulating Hormone; Follow-Up Studies; Food Microbiology; Forced Expiratory Volume; Forkhead Transcription Factors; Frontotemporal Dementia; G-Quadruplexes; Galactose; Gastroenteritis; Gastrointestinal Diseases; Gastrointestinal Microbiome; Gastrointestinal Neoplasms; Gastrointestinal Tract; Gene Frequency; Genetic Association Studies; Genetic Predisposition to Disease; Genital Neoplasms, Female; Genome-Wide Association Study; Genome, Viral; Genomics; Genotype; Glucose; Glutathione; Glycerol; Gold; Graphite; GTPase-Activating Proteins; Heat-Shock Proteins; Heme Oxygenase-1; Hepacivirus; Hepatitis C; Hepatocytes; Histamine; Histocompatibility Antigens Class II; Hoarseness; Hospice and Palliative Care Nursing; Humans; Hydrogen; Hydrogen Peroxide; Hydrogen Sulfide; Hydroxybenzoates; Hydroxyl Radical; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperthermia, Induced; Hysteroscopy; Immunoassay; Indigo Carmine; Inflammation; Inflammatory Bowel Diseases; Insulin Resistance; Intensive Care Units; Interleukin-11; Interleukin-6; Interleukins; Iodine Radioisotopes; Iran; Iridium; Islets of Langerhans; Kinetics; Lactation; Lactobacillus; Lactobacillus plantarum; Lamins; Latin America; Lead; Lectins; Leukopenia; Ligands; Limit of Detection; Lipopolysaccharides; Lipoprotein Lipase; Liver; Liver Cirrhosis; Liver Neoplasms; Lolium; Luminescent Measurements; Luminol; Lung; Luteinizing Hormone; Macrophages; Magnetic Phenomena; Magnetic Resonance Imaging; Male; Malnutrition; Maltose; Manganese Compounds; Maternal Nutritional Physiological Phenomena; Melatonin; Metabolic Engineering; Metal Nanoparticles; Metallocenes; Metaplasia; Methicillin-Resistant Staphylococcus aureus; Methylation; Mevalonic Acid; Mexico; Mice; Mice, Inbred C57BL; Mice, Transgenic; Microbial Sensitivity Tests; Microbiota; MicroRNAs; Milk; Mitomycin; Molecular Diagnostic Techniques; Molecular Docking Simulation; Monte Carlo Method; Moringa oleifera; Multiple Sclerosis; Muscle Strength; Muscle, Skeletal; Nanocomposites; Nanotubes, Carbon; Neoadjuvant Therapy; Neoplasms; Neurodegenerative Diseases; Neurotransmitter Agents; NF-E2-Related Factor 2; Nickel; Nitrogen Dioxide; Non-alcoholic Fatty Liver Disease; Nucleic Acid Amplification Techniques; Nucleic Acid Hybridization; Nucleocapsid Proteins; Nutritional Status; Obesity; Osteogenesis; Osteosarcoma; Oxidation-Reduction; Oxides; Oxygen; Oxyquinoline; Pain; Palliative Care; Pancreatic Neoplasms; Pandemics; Particulate Matter; Peroxidase; Peroxidases; Phagocytosis; Phaseolus; Photothermal Therapy; Point-of-Care Systems; Polyethyleneimine; Polymers; Polymorphism, Single Nucleotide; Polysomnography; Postoperative Complications; Pregnancy; Pregnant Women; Prenatal Exposure Delayed Effects; Prevalence; Printing, Three-Dimensional; Probability; Probiotics; Prognosis; Prophages; Prospective Studies; Proteomics; Proto-Oncogene Proteins; Pseudomonas aeruginosa; Pseudomonas putida; Pulmonary Disease, Chronic Obstructive; Pulmonary Embolism; Pyridines; Pyrroles; Quality of Life; Quinolones; Rabbits; Rats; Rats, Sprague-Dawley; Reactive Oxygen Species; Real-Time Polymerase Chain Reaction; Receptors, Histamine; Receptors, Histamine H2; Recombinases; Rectal Neoplasms; Reperfusion Injury; Respiration; Respiratory Function Tests; Respiratory Rate; Respiratory Sounds; Retrospective Studies; rho GTP-Binding Proteins; Risk Assessment; Risk Factors; RNA; RNA, Messenger; RNA, Ribosomal, 16S; Robotic Surgical Procedures; Running; Rural Population; Saccharomyces cerevisiae; Salpingectomy; Sarcopenia; SARS-CoV-2; Seeds; Semen; Sensitivity and Specificity; Sepsis; Shock, Septic; Signal Transduction; Silicon Dioxide; Silver; Sirtuin 1; Skin Neoplasms; Sleep Apnea, Obstructive; Soil; Spain; Spectrum Analysis, Raman; Sperm Retrieval; Spermatozoa; Spirometry; Staphylococcus aureus; STAT3 Transcription Factor; Stereoisomerism; Sterilization, Tubal; Stroke Volume; Sulfadiazine; Sulfites; Superoxide Dismutase; Surface Plasmon Resonance; tau Proteins; Testis; Testosterone; Thioredoxin-Disulfide Reductase; Thyroid Neoplasms; Thyroidectomy; Trans-Activators; Transcription Factor AP-1; Treatment Outcome; Triazoles; Triclosan; Trifluridine; Tumor Microenvironment; Tumor Necrosis Factor-alpha; United States; Uracil; Vagina; Vegetables; Ventricular Function, Left; Ventricular Pressure; Vibrio cholerae; Vietnam; Virulence; Vital Capacity; Vitrification; Walking; Water; Water Pollutants, Radioactive; Whole Genome Sequencing; Wind; YAP-Signaling Proteins; Zeolites; Zinc Oxide | 2023 |
Prophylactic antibiotics for adults with chronic obstructive pulmonary disease: a network meta-analysis.
Topics: Adult; Aged; Anti-Bacterial Agents; Antibiotic Prophylaxis; Bacterial Load; Bayes Theorem; Bias; Disease Progression; Female; Forced Expiratory Volume; Humans; Macrolides; Male; Middle Aged; Network Meta-Analysis; Pulmonary Disease, Chronic Obstructive; Quality of Life; Quinolones; Randomized Controlled Trials as Topic; Tetracyclines; Treatment Outcome | 2021 |
Population Pharmacokinetic Analysis of Indacaterol/Glycopyrronium/Mometasone Furoate After Administration of Combination Therapies Using the Breezhaler
Topics: Administration, Inhalation; Adolescent; Adult; Aged; Anti-Asthmatic Agents; Asthma; Child; Clinical Trials, Phase III as Topic; Dose-Response Relationship, Drug; Drug Combinations; Female; Glycopyrrolate; Humans; Indans; Male; Middle Aged; Models, Biological; Mometasone Furoate; Nebulizers and Vaporizers; Pulmonary Disease, Chronic Obstructive; Quinolones; Randomized Controlled Trials as Topic; Young Adult | 2021 |
Role of dual bronchodilators in COPD: A review of the current evidence for indacaterol/glycopyrronium.
Topics: Administration, Inhalation; Adrenergic beta-2 Receptor Agonists; Animals; Bronchodilator Agents; Drug Combinations; Glucocorticoids; Glycopyrrolate; Humans; Indans; Muscarinic Antagonists; Pulmonary Disease, Chronic Obstructive; Quinolones; Severity of Illness Index | 2017 |
Comparative effectiveness of indacaterol/glycopyrronium in the treatment of chronic obstructive pulmonary disease.
Topics: Adrenal Cortex Hormones; Bronchodilator Agents; Comparative Effectiveness Research; Drug Combinations; Glycopyrrolate; Humans; Indans; Muscarinic Antagonists; Observational Studies as Topic; Pulmonary Disease, Chronic Obstructive; Quinolones; Randomized Controlled Trials as Topic; Treatment Outcome | 2017 |
Indacaterol/glycopyrronium: a dual bronchodilator for COPD.
Topics: Adrenergic beta-2 Receptor Agonists; Bronchodilator Agents; Drug Approval; Drug Combinations; Glycopyrrolate; Humans; Indans; Muscarinic Antagonists; Pulmonary Disease, Chronic Obstructive; Quinolones; Treatment Outcome | 2018 |
Dual bronchodilator therapy for chronic obstructive pulmonary disease: evidence for the efficacy and Safety of fixed dose combination treatments in the setting of recent guideline updates.
Topics: Administration, Inhalation; Benzoxazines; Benzyl Alcohols; Bronchodilator Agents; Chlorobenzenes; Delayed-Action Preparations; Drug Combinations; Formoterol Fumarate; Glycopyrrolate; Humans; Indans; Muscarinic Antagonists; Practice Guidelines as Topic; Pulmonary Disease, Chronic Obstructive; Quinolones; Quinuclidines; Tiotropium Bromide; Tropanes | 2018 |
Mini Review: Chronic obstructive pulmonary disease, its new drug treatments and strategies: A review.
Topics: Administration, Inhalation; Adrenergic beta-2 Receptor Agonists; Aminopyridines; Benzamides; Bronchodilator Agents; Cyclopropanes; Humans; Indans; Phosphodiesterase 4 Inhibitors; Pulmonary Disease, Chronic Obstructive; Quinolones; Treatment Outcome | 2018 |
The safety of indacaterol for the treatment of COPD.
Topics: Administration, Inhalation; Adrenergic beta-2 Receptor Agonists; Animals; Bronchodilator Agents; Delayed-Action Preparations; Drug Administration Schedule; Humans; Indans; Pulmonary Disease, Chronic Obstructive; Quinolones; Time Factors | 2018 |
Improvement of physical activity in chronic obstructive pulmonary disease by pulmonary rehabilitation and pharmacological treatment.
Topics: Adrenergic beta-2 Receptor Agonists; Behavior; Counseling; Delayed-Action Preparations; Drug Therapy, Combination; Energy Metabolism; Exercise; Formoterol Fumarate; Glycopyrrolate; Humans; Indans; Muscarinic Antagonists; Pulmonary Disease, Chronic Obstructive; Quality of Life; Quinolones; Self Efficacy; Terbutaline; Treatment Outcome; Tropanes | 2018 |
Fixed-Dose Combinations of Long-Acting Bronchodilators for the Management of COPD: Global and Asian Perspectives.
Topics: Administration, Inhalation; Adrenergic beta-2 Receptor Agonists; Asian People; Benzoxazines; Benzyl Alcohols; Bronchodilator Agents; Chlorobenzenes; Drug Combinations; Formoterol Fumarate; Glycopyrrolate; Humans; Indans; Muscarinic Antagonists; Pulmonary Disease, Chronic Obstructive; Quinolones; Quinuclidines; Tiotropium Bromide; Treatment Outcome; Tropanes | 2019 |
Improving the quality of life in patients with chronic obstructive pulmonary disease: focus on indacaterol.
Topics: Adrenergic beta-2 Receptor Agonists; Albuterol; Bronchodilator Agents; Clinical Trials as Topic; Dyspnea; Exercise Tolerance; Humans; Indans; Pulmonary Disease, Chronic Obstructive; Quality of Life; Quinolones; Severity of Illness Index | 2013 |
Ten years of tiotropium: clinical impact and patient perspectives.
Topics: Adrenergic beta-2 Receptor Agonists; Albuterol; Bronchodilator Agents; Dyspnea; Ethanolamines; Formoterol Fumarate; Humans; Indans; Medication Adherence; Mucociliary Clearance; Nebulizers and Vaporizers; Pulmonary Disease, Chronic Obstructive; Quality of Life; Quinolones; Salmeterol Xinafoate; Scopolamine Derivatives; Tiotropium Bromide | 2013 |
Indacaterol on dyspnea in chronic obstructive pulmonary disease: a systematic review and meta-analysis of randomized placebo-controlled trials.
Topics: Adrenergic beta-2 Receptor Agonists; Dyspnea; Humans; Indans; Placebos; Pulmonary Disease, Chronic Obstructive; Quinolones; Randomized Controlled Trials as Topic | 2013 |
Symptom variability in COPD: a narrative review.
Topics: Activities of Daily Living; Bronchodilator Agents; Clinical Trials as Topic; Disease Progression; Ethanolamines; Forced Expiratory Volume; Formoterol Fumarate; Humans; Indans; Patient Care Management; Periodicity; Pulmonary Disease, Chronic Obstructive; Quality of Life; Quinolones; Surveys and Questionnaires; Symptom Assessment | 2013 |
Indacaterol/glycopyrronium bromide fixed-dose combination for the treatment of COPD.
Topics: Adrenergic beta-2 Receptor Agonists; Drug Combinations; Glycopyrrolate; Humans; Indans; Muscarinic Antagonists; Pulmonary Disease, Chronic Obstructive; Quinolones | 2013 |
Indacaterol: a comprehensive review.
Topics: Administration, Inhalation; Bronchodilator Agents; Clinical Trials as Topic; Delayed-Action Preparations; Dose-Response Relationship, Drug; Forced Expiratory Volume; Humans; Indans; Lung; Physical Therapy Modalities; Pulmonary Disease, Chronic Obstructive; Quinolones; Respiration; Risk Reduction Behavior; Treatment Outcome | 2013 |
Indacaterol for chronic obstructive pulmonary disease: systematic review and meta-analysis.
Topics: Bronchodilator Agents; Humans; Indans; Pulmonary Disease, Chronic Obstructive; Quinolones; Scopolamine Derivatives; Tiotropium Bromide; Treatment Outcome | 2013 |
Role of indacaterol and the newer very long-acting β2-agonists in patients with stable COPD: a review.
Topics: Adrenergic beta-2 Receptor Agonists; Bronchodilator Agents; Drug Administration Schedule; Drug Design; Humans; Indans; Lung; Medication Adherence; Pulmonary Disease, Chronic Obstructive; Quinolones; Time Factors; Treatment Outcome | 2013 |
Comparative efficacy of long-acting bronchodilators for COPD: a network meta-analysis.
Topics: Albuterol; Bayes Theorem; Bronchodilator Agents; Delayed-Action Preparations; Dose-Response Relationship, Drug; Ethanolamines; Formoterol Fumarate; Glycopyrrolate; Humans; Indans; Pulmonary Disease, Chronic Obstructive; Quinolones; Randomized Controlled Trials as Topic; Salmeterol Xinafoate; Scopolamine Derivatives; Severity of Illness Index; Tiotropium Bromide; Treatment Outcome | 2013 |
Use of indacaterol for the treatment of COPD: a pharmacokinetic evaluation.
Topics: Animals; Bronchodilator Agents; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Drug Interactions; Humans; Indans; Pulmonary Disease, Chronic Obstructive; Quinolones | 2014 |
New developments in the management of COPD: clinical utility of indacaterol 75 μg.
Topics: Adrenergic beta-2 Receptor Agonists; Bronchoconstriction; Bronchodilator Agents; Drug Administration Schedule; Humans; Indans; Lung; Pulmonary Disease, Chronic Obstructive; Quinolones; Time Factors; Treatment Outcome | 2014 |
Efficacy and safety of a fixed-dose combination of indacaterol and Glycopyrronium for the treatment of COPD: a systematic review.
Topics: Dose-Response Relationship, Drug; Drug Therapy, Combination; Glycopyrrolate; Humans; Indans; Muscarinic Antagonists; Practice Guidelines as Topic; Pulmonary Disease, Chronic Obstructive; Quinolones; Randomized Controlled Trials as Topic; Treatment Outcome | 2014 |
QVA149 (indacaterol/glycopyrronium fixed-dose combination): a review of its use in patients with chronic obstructive pulmonary disease.
Topics: Administration, Inhalation; Bronchodilator Agents; Clinical Trials, Phase III as Topic; Drug Combinations; Glycopyrrolate; Humans; Indans; Pulmonary Disease, Chronic Obstructive; Quinolones; Respiratory Function Tests; Severity of Illness Index; Treatment Outcome | 2014 |
Clinical benefit of fixed-dose dual bronchodilation with glycopyrronium and indacaterol once daily in patients with chronic obstructive pulmonary disease: a systematic review.
Topics: Administration, Inhalation; Adrenergic beta-2 Receptor Agonists; Bronchodilator Agents; Drug Administration Schedule; Drug Combinations; Glycopyrrolate; Humans; Indans; Lung; Muscarinic Antagonists; Pulmonary Disease, Chronic Obstructive; Quinolones; Randomized Controlled Trials as Topic; Recovery of Function; Time Factors; Treatment Outcome | 2014 |
Recent advances in COPD disease management with fixed-dose long-acting combination therapies.
Topics: Adrenal Cortex Hormones; Adrenergic beta-Agonists; Albuterol; Benzyl Alcohols; Bronchodilator Agents; Chlorobenzenes; Disease Management; Disease Progression; Drug Combinations; Ethanolamines; Formoterol Fumarate; Glycopyrrolate; Humans; Indans; Muscarinic Antagonists; Pulmonary Disease, Chronic Obstructive; Quinolones; Quinuclidines; Salmeterol Xinafoate; Scopolamine Derivatives; Tiotropium Bromide; Treatment Outcome | 2014 |
Indacaterol in the Treatment of Chronic Obstructive Pulmonary Disease: From Clinical Trials to Daily Practice.
Topics: Humans; Indans; Pulmonary Disease, Chronic Obstructive; Quinolones; Randomized Controlled Trials as Topic; Translational Research, Biomedical | 2014 |
Once-daily long-acting beta-agonists for chronic obstructive pulmonary disease: an indirect comparison of olodaterol and indacaterol.
Topics: Adrenergic beta-2 Receptor Agonists; Benzoxazines; Bronchodilator Agents; Drug Administration Schedule; Forced Expiratory Volume; Humans; Indans; Lung; Pulmonary Disease, Chronic Obstructive; Quinolones; Randomized Controlled Trials as Topic; Time Factors; Treatment Outcome | 2014 |
Turning a molecule into a medicine: the development of indacaterol as a novel once-daily bronchodilator treatment for patients with COPD.
Topics: Bronchodilator Agents; Humans; Indans; Molecular Structure; Pulmonary Disease, Chronic Obstructive; Quinolones | 2014 |
[The combination of indacaterol and glycopyrronium has effects on symptoms, lung function, and rate of exacerbations in COPD patients].
Topics: Administration, Inhalation; Adrenergic beta-2 Receptor Agonists; Disease Progression; Drug Combinations; Forced Expiratory Volume; Glycopyrrolate; Humans; Indans; Muscarinic Antagonists; Pulmonary Disease, Chronic Obstructive; Quality of Life; Quinolones | 2014 |
Monotherapy with indacaterol once daily reduces the rate of exacerbations in patients with moderate-to-severe COPD: Post-hoc pooled analysis of 6 months data from three large phase III trials.
Topics: Adrenergic beta-2 Receptor Agonists; Bronchodilator Agents; Clinical Trials, Phase III as Topic; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Forced Expiratory Volume; Humans; Indans; Kaplan-Meier Estimate; Pulmonary Disease, Chronic Obstructive; Quinolones; Randomized Controlled Trials as Topic | 2015 |
Treatment of chronic obstructive pulmonary disease by dual bronchodilation with coformulation of indacaterol/glycopyrronium.
Topics: Acetylcholine; Bronchoconstriction; Bronchodilator Agents; Drug Combinations; Glycopyrrolate; Humans; Indans; Pulmonary Disease, Chronic Obstructive; Quinolones | 2014 |
Indacaterol, a once-daily beta2-agonist, versus twice-daily beta₂-agonists or placebo for chronic obstructive pulmonary disease.
Topics: Adrenergic beta-2 Receptor Agonists; Drug Administration Schedule; Forced Expiratory Volume; Formoterol Fumarate; Humans; Indans; Pulmonary Disease, Chronic Obstructive; Quinolones; Randomized Controlled Trials as Topic; Salmeterol Xinafoate | 2015 |
Profile of inhaled glycopyrronium bromide as monotherapy and in fixed-dose combination with indacaterol maleate for the treatment of COPD.
Topics: Administration, Inhalation; Adrenergic beta-2 Receptor Agonists; Animals; Bronchodilator Agents; Drug Combinations; Glycopyrrolate; Humans; Indans; Lung; Muscarinic Antagonists; Pulmonary Disease, Chronic Obstructive; Quinolones; Severity of Illness Index; Treatment Outcome | 2015 |
Combination therapy with indacaterol and glycopyrronium bromide in the management of COPD: an update on the evidence for efficacy and safety.
Topics: Administration, Inhalation; Adrenergic beta-2 Receptor Agonists; Bronchodilator Agents; Drug Combinations; Glycopyrrolate; Humans; Indans; Lung; Muscarinic Antagonists; Pulmonary Disease, Chronic Obstructive; Quinolones; Treatment Outcome | 2015 |
The impact of treatment with indacaterol in patients with COPD: A post-hoc analysis according to GOLD 2011 categories A to D.
Topics: Aged; Bronchodilator Agents; Clinical Trials, Phase III as Topic; Dose-Response Relationship, Drug; Double-Blind Method; Female; Forced Expiratory Volume; Humans; Indans; Male; Middle Aged; Pulmonary Disease, Chronic Obstructive; Quinolones; Randomized Controlled Trials as Topic; Treatment Outcome | 2015 |
Comparison of clinical efficacy and safety between indacaterol and tiotropium in COPD: meta-analysis of randomized controlled trials.
Topics: Adrenergic beta-2 Receptor Agonists; Bronchodilator Agents; Forced Expiratory Volume; Humans; Indans; Pulmonary Disease, Chronic Obstructive; Quinolones; Randomized Controlled Trials as Topic; Tiotropium Bromide; Treatment Outcome | 2015 |
QVA149 (indacaterol/glycopyrronium) for the treatment of chronic obstructive pulmonary disease.
Topics: Administration, Inhalation; Bronchodilator Agents; Clinical Trials, Phase III as Topic; Drug Combinations; Dyspnea; Glycopyrrolate; Humans; Indans; Pulmonary Disease, Chronic Obstructive; Quality of Life; Quinolones | 2015 |
Role of combined indacaterol and glycopyrronium bromide (QVA149) for the treatment of COPD in Japan.
Topics: Administration, Inhalation; Adrenergic beta-2 Receptor Agonists; Bronchodilator Agents; Drug Administration Schedule; Drug Combinations; Evidence-Based Medicine; Forced Expiratory Volume; Glycopyrrolate; Humans; Indans; Japan; Lung; Muscarinic Antagonists; Nebulizers and Vaporizers; Pulmonary Disease, Chronic Obstructive; Quinolones; Randomized Controlled Trials as Topic; Time Factors; Treatment Outcome | 2015 |
Clinical role of dual bronchodilation with an indacaterol-glycopyrronium combination in the management of COPD: its impact on patient-related outcomes and quality of life.
Topics: Adrenergic alpha-2 Receptor Agonists; Bronchodilator Agents; Drug Combinations; Glycopyrrolate; Humans; Indans; Lung; Muscarinic Antagonists; Pulmonary Disease, Chronic Obstructive; Quality of Life; Quinolones; Treatment Outcome | 2015 |
Comparative efficacy of combination bronchodilator therapies in COPD: a network meta-analysis.
Topics: Bronchodilator Agents; Drug Combinations; Drug Therapy, Combination; Dyspnea; Forced Expiratory Volume; Formoterol Fumarate; Glycopyrrolate; Humans; Indans; Pulmonary Disease, Chronic Obstructive; Quinolones; Randomized Controlled Trials as Topic; Salmeterol Xinafoate; Tiotropium Bromide; Treatment Outcome | 2015 |
Effect of Indacaterol on Cough and Phlegm in Chronic Obstructive Pulmonary Disease Patients: A Meta-Analysis of Five Randomized Controlled Trials.
Topics: Administration, Inhalation; Anti-Bacterial Agents; Bronchodilator Agents; Cough; Dyspnea; Forced Expiratory Volume; Humans; Indans; Placebos; Pulmonary Disease, Chronic Obstructive; Quinolones; Sputum; Surveys and Questionnaires; Treatment Outcome | 2015 |
Long-acting beta2-agonist in addition to tiotropium versus either tiotropium or long-acting beta2-agonist alone for chronic obstructive pulmonary disease.
Topics: Adrenergic beta-2 Receptor Agonists; Aged; Albuterol; Bronchodilator Agents; Ethanolamines; Formoterol Fumarate; Humans; Indans; Middle Aged; Pulmonary Disease, Chronic Obstructive; Quality of Life; Quinolones; Randomized Controlled Trials as Topic; Salmeterol Xinafoate; Scopolamine Derivatives; Tiotropium Bromide | 2015 |
Mortality and drug therapy in patients with chronic obstructive pulmonary disease: a network meta-analysis.
Topics: Albuterol; Aminopyridines; Beclomethasone; Benzamides; Benzyl Alcohols; Bronchodilator Agents; Budesonide; Chlorobenzenes; Cyclopropanes; Fluticasone-Salmeterol Drug Combination; Formoterol Fumarate; Glucocorticoids; Humans; Indans; Ipratropium; Proportional Hazards Models; Pulmonary Disease, Chronic Obstructive; Quinolones; Survival Rate; Theophylline; Tiotropium Bromide; Triamcinolone | 2015 |
Effect of tiotropium on COPD exacerbations: A systematic review.
Topics: Administration, Inhalation; Bronchodilator Agents; Cholinergic Antagonists; Glycopyrrolate; Humans; Indans; Muscarinic Antagonists; Pulmonary Disease, Chronic Obstructive; Quinolones; Randomized Controlled Trials as Topic; Tiotropium Bromide | 2016 |
[LAMA/LABA fixed dose combination for treatment of COPD].
Topics: Adrenergic beta-2 Receptor Agonists; Benzoxazines; Benzyl Alcohols; Bronchodilator Agents; Chlorobenzenes; Delayed-Action Preparations; Drug Combinations; Forced Expiratory Volume; Glycopyrrolate; Humans; Indans; Muscarinic Antagonists; Pulmonary Disease, Chronic Obstructive; Quinolones; Quinuclidines; Respiratory Function Tests; Tiotropium Bromide; Treatment Outcome | 2016 |
Indacaterol, a novel inhaled, once-daily, long-acting beta2-agonist for the treatment of obstructive airways diseases.
Topics: Adrenergic beta-Agonists; Asthma; Bronchodilator Agents; Clinical Trials as Topic; Delayed-Action Preparations; Humans; Indans; Pulmonary Disease, Chronic Obstructive; Quinolones | 2009 |
[Efficacy and safety of indacaterol - new long-acting beta(2) agonist].
Topics: Administration, Inhalation; Adrenergic beta-Agonists; Asthma; Dose-Response Relationship, Drug; Forced Expiratory Volume; Humans; Indans; Nebulizers and Vaporizers; Pulmonary Disease, Chronic Obstructive; Quinolones | 2010 |
Indacaterol for chronic obstructive pulmonary disease (COPD).
Topics: Adrenergic beta-Agonists; Adult; Animals; Bronchodilator Agents; Clinical Trials as Topic; Delayed-Action Preparations; Humans; Indans; Pulmonary Disease, Chronic Obstructive; Quinolones | 2010 |
[Diseases of the lung and air passages 2010].
Topics: Administration, Inhalation; Adrenergic beta-Agonists; Aminopyridines; Asthma; Benzamides; Cyclopropanes; Drug Therapy, Combination; Humans; Hypertension, Pulmonary; Indans; Lung Diseases; Lung Neoplasms; Neoplasm Staging; Phosphodiesterase 4 Inhibitors; Pneumonia, Bacterial; Practice Guidelines as Topic; Pulmonary Disease, Chronic Obstructive; Quinolones | 2010 |
Indacaterol maleate for the treatment of chronic obstructive pulmonary disease.
Topics: Adrenergic beta-Agonists; Animals; Bronchodilator Agents; Drug Administration Schedule; Humans; Indans; Maleates; Pulmonary Disease, Chronic Obstructive; Quinolones; Treatment Outcome | 2010 |
An update on the use of indacaterol in patients with COPD.
Topics: Adrenergic beta-2 Receptor Agonists; Humans; Indans; Pulmonary Disease, Chronic Obstructive; Quinolones | 2011 |
Indacaterol: in chronic obstructive pulmonary disease.
Topics: Adrenergic beta-2 Receptor Agonists; Animals; Clinical Trials, Phase III as Topic; Forced Expiratory Volume; Humans; Indans; Pulmonary Disease, Chronic Obstructive; Quinolones; Vasodilator Agents | 2010 |
[Indacaterol is a new once-daily beta2-agonist for treatment of COPD].
Topics: Administration, Inhalation; Adrenergic beta-Agonists; Forced Expiratory Volume; Humans; Indans; Pulmonary Disease, Chronic Obstructive; Quality of Life; Quinolones; Treatment Outcome | 2010 |
Characterization of the bronchodilatory dose response to indacaterol in patients with chronic obstructive pulmonary disease using model-based approaches.
Topics: Adrenergic beta-2 Receptor Agonists; Bronchodilator Agents; Controlled Clinical Trials as Topic; Decision Support Techniques; Dose-Response Relationship, Drug; Drug Dosage Calculations; Forced Expiratory Volume; Humans; Indans; Lung; Nonlinear Dynamics; Pulmonary Disease, Chronic Obstructive; Quinolones; Severity of Illness Index; Time Factors; Treatment Outcome | 2011 |
Comparative efficacy of indacaterol 150 μg and 300 μg versus fixed-dose combinations of formoterol + budesonide or salmeterol + fluticasone for the treatment of chronic obstructive pulmonary disease--a network meta-analysis.
Topics: Albuterol; Androstadienes; Bronchodilator Agents; Budesonide; Drug Combinations; Ethanolamines; Fluticasone-Salmeterol Drug Combination; Formoterol Fumarate; Humans; Indans; Pulmonary Disease, Chronic Obstructive; Quinolones; Randomized Controlled Trials as Topic; Treatment Outcome | 2011 |
Profiling the bronchodilator effects of the novel ultra-long-acting β2-agonist indacaterol against established treatments in chronic obstructive pulmonary disease.
Topics: Adrenergic beta-2 Receptor Agonists; Bronchodilator Agents; Delayed-Action Preparations; Forced Expiratory Volume; Humans; Indans; Pulmonary Disease, Chronic Obstructive; Quinolones; Time Factors | 2011 |
Effect of long-acting beta-agonists on the frequency of COPD exacerbations: a meta-analysis.
Topics: Administration, Inhalation; Adrenergic beta-2 Receptor Agonists; Albuterol; Bronchodilator Agents; Delayed-Action Preparations; Drug Therapy, Combination; Ethanolamines; Formoterol Fumarate; Glucocorticoids; Humans; Indans; Pulmonary Disease, Chronic Obstructive; Quinolones; Randomized Controlled Trials as Topic; Salmeterol Xinafoate | 2012 |
Efficacy of indacaterol in the treatment of patients with COPD.
Topics: Aged; Albuterol; Bronchodilator Agents; Clinical Trials as Topic; Female; Humans; Indans; Male; Middle Aged; Pulmonary Disease, Chronic Obstructive; Quinolones; Randomized Controlled Trials as Topic; Severity of Illness Index | 2011 |
Long-acting β-adrenoceptor agonists in the management of COPD: focus on indacaterol.
Topics: Adrenergic beta-2 Receptor Agonists; Bronchodilator Agents; Drug Administration Schedule; Evidence-Based Medicine; Humans; Indans; Lung; Pulmonary Disease, Chronic Obstructive; Quinolones; Treatment Outcome | 2011 |
Indacaterol. A long-acting beta-2 agonist, no advantages in COPD.
Topics: Adrenergic beta-2 Receptor Agonists; Bronchodilator Agents; Humans; Indans; Pulmonary Disease, Chronic Obstructive; Quinolones | 2011 |
Bronchodilator efficacy and safety of indacaterol 150 μg once daily in patients with COPD: an analysis of pooled data.
Topics: Administration, Inhalation; Adrenergic beta-2 Receptor Agonists; Aged; Albuterol; Bronchodilator Agents; Drug Administration Schedule; Female; Forced Expiratory Volume; Humans; Indans; Lung; Male; Middle Aged; Pulmonary Disease, Chronic Obstructive; Quinolones; Randomized Controlled Trials as Topic; Severity of Illness Index; Time Factors; Treatment Outcome | 2011 |
Safety of indacaterol in the treatment of patients with COPD.
Topics: Administration, Inhalation; Adrenergic beta-2 Receptor Agonists; Aged; Bronchodilator Agents; Drug Administration Schedule; Female; Humans; Indans; Male; Middle Aged; Patient Selection; Proportional Hazards Models; Pulmonary Disease, Chronic Obstructive; Quinolones; Risk Assessment; Risk Factors; Severity of Illness Index; Time Factors; Treatment Outcome | 2011 |
Correlating changes in lung function with patient outcomes in chronic obstructive pulmonary disease: a pooled analysis.
Topics: Adrenergic beta-2 Receptor Agonists; Aged; Bronchodilator Agents; Clinical Trials, Phase III as Topic; Evidence-Based Medicine; Female; Forced Expiratory Volume; Humans; Indans; Linear Models; Lung; Male; Middle Aged; Predictive Value of Tests; Pulmonary Disease, Chronic Obstructive; Quinolones; Randomized Controlled Trials as Topic; Recovery of Function; Severity of Illness Index; Time Factors; Treatment Outcome | 2011 |
Indacaterol: a review of its use as maintenance therapy in patients with chronic obstructive pulmonary disease.
Topics: Administration, Inhalation; Adrenergic beta-2 Receptor Agonists; Adult; Cost-Benefit Analysis; Dose-Response Relationship, Drug; Drug Administration Schedule; Forced Expiratory Volume; Humans; Indans; Maintenance Chemotherapy; Pulmonary Disease, Chronic Obstructive; Quinolones; Randomized Controlled Trials as Topic; Respiratory Function Tests; Treatment Outcome | 2012 |
Comparison of indacaterol with tiotropium or twice-daily long-acting β -agonists for stable COPD: a systematic review.
Topics: Adrenergic beta-Agonists; Bronchodilator Agents; Evidence-Based Medicine; Humans; Indans; Pulmonary Disease, Chronic Obstructive; Quinolones; Randomized Controlled Trials as Topic; Respiratory Function Tests; Scopolamine Derivatives; Tiotropium Bromide | 2012 |
Comparative efficacy of indacaterol in chronic obstructive pulmonary disease.
Topics: Administration, Inhalation; Adrenergic beta-2 Receptor Agonists; Bronchodilator Agents; Drug Administration Schedule; Drug Therapy, Combination; Evidence-Based Medicine; Humans; Indans; Lung; Pulmonary Disease, Chronic Obstructive; Quinolones; Treatment Outcome | 2012 |
Indacaterol: a novel long-acting β(2) -agonist.
Topics: Administration, Inhalation; Adrenergic beta-2 Receptor Agonists; Asthma; Clinical Trials as Topic; Delayed-Action Preparations; Dose-Response Relationship, Drug; Drug Administration Schedule; Dry Powder Inhalers; Humans; Indans; Metered Dose Inhalers; Pulmonary Disease, Chronic Obstructive; Quinolones; Treatment Outcome | 2012 |
Long-acting beta(2)-agonist in addition to tiotropium versus either tiotropium or long-acting beta(2)-agonist alone for chronic obstructive pulmonary disease.
Topics: Adrenergic beta-2 Receptor Agonists; Aged; Albuterol; Bronchodilator Agents; Ethanolamines; Formoterol Fumarate; Humans; Indans; Middle Aged; Pulmonary Disease, Chronic Obstructive; Quality of Life; Quinolones; Salmeterol Xinafoate; Scopolamine Derivatives; Tiotropium Bromide | 2012 |
Limitations of model based dose selection for indacaterol in patients with chronic obstructive pulmonary disease.
Topics: Adrenergic beta-2 Receptor Agonists; Bronchodilator Agents; Decision Support Techniques; Dose-Response Relationship, Drug; Drug Approval; Drug Discovery; Drug Dosage Calculations; Forced Expiratory Volume; Humans; Indans; Lung; Models, Theoretical; Pulmonary Disease, Chronic Obstructive; Quinolones; Reproducibility of Results; Severity of Illness Index; Time Factors; United States | 2012 |
Efficacy of once-daily indacaterol 75 μg relative to alternative bronchodilators in COPD: a study level and a patient level network meta-analysis.
Topics: Adrenergic beta-2 Receptor Antagonists; Adult; Aged; Aged, 80 and over; Albuterol; Bronchodilator Agents; Dose-Response Relationship, Drug; Ethanolamines; Female; Formoterol Fumarate; Humans; Indans; Male; Middle Aged; Pulmonary Disease, Chronic Obstructive; Quinolones; Randomized Controlled Trials as Topic; Salmeterol Xinafoate; Scopolamine Derivatives; Tiotropium Bromide; Treatment Outcome | 2012 |
[Pharmacological and clinical profile of indacaterol maleate (Onbrez®), an inhaled long-acting β₂-adrenoceptor agonist].
Topics: Administration, Inhalation; Adrenergic beta-2 Receptor Agonists; Animals; Bronchodilator Agents; Clinical Trials as Topic; Delayed-Action Preparations; Dose-Response Relationship, Drug; Guinea Pigs; Humans; Indans; Japan; Pulmonary Disease, Chronic Obstructive; Quinolones | 2012 |
Efficacy of indacaterol 75 μg versus fixed-dose combinations of formoterol-budesonide or salmeterol-fluticasone for COPD: a network meta-analysis.
Topics: Albuterol; Androstadienes; Bronchodilator Agents; Budesonide; Drug Combinations; Drug Therapy, Combination; Dyspnea; Ethanolamines; Fluticasone-Salmeterol Drug Combination; Forced Expiratory Volume; Formoterol Fumarate; Glucocorticoids; Humans; Indans; Outcome Assessment, Health Care; Pulmonary Disease, Chronic Obstructive; Quinolones; Randomized Controlled Trials as Topic | 2012 |
Tiotropium versus long-acting beta-agonists for stable chronic obstructive pulmonary disease.
Topics: Adrenergic beta-2 Receptor Agonists; Albuterol; Bronchodilator Agents; Cost-Benefit Analysis; Disease Progression; Ethanolamines; Formoterol Fumarate; Hospitalization; Humans; Indans; Pulmonary Disease, Chronic Obstructive; Quality of Life; Quinolones; Randomized Controlled Trials as Topic; Salmeterol Xinafoate; Scopolamine Derivatives; Tiotropium Bromide | 2012 |
Indacaterol therapy in patients with COPD not receiving other maintenance treatment.
Topics: Bronchodilator Agents; Double-Blind Method; Female; Forced Expiratory Volume; Humans; Indans; Maintenance Chemotherapy; Male; Middle Aged; Pulmonary Disease, Chronic Obstructive; Quinolones; Randomized Controlled Trials as Topic; Treatment Outcome; Vital Capacity | 2012 |
A review of the advances in chronic obstructive pulmonary disease treatment.
Topics: Aminopyridines; Benzamides; Bronchodilator Agents; Cyclopropanes; Humans; Indans; Phosphodiesterase 4 Inhibitors; Pulmonary Disease, Chronic Obstructive; Quality of Life; Quinolones; Randomized Controlled Trials as Topic; Scopolamine Derivatives; Tiotropium Bromide | 2012 |
Effects of long-acting bronchodilators in COPD patients according to COPD severity and ICS use.
Topics: Administration, Inhalation; Adrenergic beta-2 Receptor Agonists; Adult; Aged; Albuterol; Bronchodilator Agents; Drug Administration Schedule; Drug Therapy, Combination; Dyspnea; Ethanolamines; Female; Forced Expiratory Volume; Formoterol Fumarate; Glucocorticoids; Humans; Indans; Male; Middle Aged; Pulmonary Disease, Chronic Obstructive; Quinolones; Randomized Controlled Trials as Topic; Salmeterol Xinafoate; Scopolamine Derivatives; Severity of Illness Index; Tiotropium Bromide; Treatment Outcome; Vital Capacity | 2013 |
Indacaterol 75 μg once daily for the treatment of patients with chronic obstructive pulmonary disease: a North American perspective.
Topics: Administration, Inhalation; Adrenergic beta-2 Receptor Agonists; Bronchodilator Agents; Drug Administration Schedule; Humans; Indans; Lung; North America; Pulmonary Disease, Chronic Obstructive; Quinolones; Severity of Illness Index; Time Factors; Treatment Outcome | 2013 |
Safety and efficacy of 12-week or longer indacaterol treatment in moderate-to-severe COPD patients: a systematic review.
Topics: Adrenergic beta-2 Receptor Agonists; Aged; Bronchodilator Agents; Chi-Square Distribution; Drug Administration Schedule; Evidence-Based Medicine; Female; Forced Expiratory Volume; Humans; Indans; Lung; Male; Middle Aged; Odds Ratio; Pulmonary Disease, Chronic Obstructive; Quinolones; Randomized Controlled Trials as Topic; Recovery of Function; Severity of Illness Index; Time Factors; Treatment Outcome; Vital Capacity | 2013 |
The safety of long-acting β2-agonists in the treatment of stable chronic obstructive pulmonary disease.
Topics: Adrenergic beta-2 Receptor Agonists; Albuterol; Blood Glucose; Cough; Ethanolamines; Formoterol Fumarate; Headache; Humans; Indans; Nasopharyngitis; Potassium; Pulmonary Disease, Chronic Obstructive; Quinolones; Respiratory Tract Infections; Salmeterol Xinafoate; Spasm; Tachycardia; Tremor | 2013 |
Macrolides, quinolones and amoxicillin/clavulanate for chronic bronchitis: a meta-analysis.
Topics: Amoxicillin; Anti-Bacterial Agents; Bronchitis; Bronchitis, Chronic; Clavulanic Acid; Clinical Trials as Topic; Humans; Macrolides; Odds Ratio; Pulmonary Disease, Chronic Obstructive; Quinolones; Randomized Controlled Trials as Topic; Sensitivity and Specificity; Treatment Outcome | 2007 |
ultra-long-acting beta2-adrenoceptor agonists: an emerging therapeutic option for asthma and COPD?
Topics: Adrenergic beta-2 Receptor Agonists; Adrenergic beta-Agonists; Amphetamines; Animals; Asthma; Bronchodilator Agents; Ethanolamines; Formoterol Fumarate; Humans; Hydroxyquinolines; Indans; Pulmonary Disease, Chronic Obstructive; Quinolones | 2007 |
108 trial(s) available for carbostyril and Pulmonary Disease, Chronic Obstructive
| Article | Year |
|---|---|
Effect of 12-week of aerobic exercise on hormones and lipid profile status in adolescent girls with polycystic ovary syndrome: A study during COVID-19.
Topics: Actin Cytoskeleton; Actins; Adaptor Proteins, Signal Transducing; Adenocarcinoma; Adenosine Triphosphate; Adsorption; Adult; Africa, Eastern; Aged; Air Pollutants; Air Pollution; Air Pollution, Indoor; Alcohol Drinking; Allergens; Alzheimer Disease; Amyotrophic Lateral Sclerosis; Animals; Anti-Bacterial Agents; Antibodies; Antibodies, Immobilized; Antigen Presentation; Antigens, CD; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Apoptosis; Aptamers, Nucleotide; Asthma; Asthma, Exercise-Induced; Atrophy; Autophagy; Azoospermia; Bacillus cereus; Bacterial Infections; Beclin-1; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Biofouling; Biological Monitoring; Biomarkers; Biomarkers, Tumor; Biosensing Techniques; Blastocyst; Bone Neoplasms; Bone Regeneration; Bronchoconstriction; Burkitt Lymphoma; C9orf72 Protein; Campylobacter; Campylobacter Infections; Campylobacter jejuni; Carcinogenesis; Carcinoma, Hepatocellular; Carcinoma, Pancreatic Ductal; Carcinoma, Squamous Cell; Cardiomyopathies; Caregivers; Carmine; Case-Control Studies; Catalysis; Cattle; Cause of Death; CCAAT-Enhancer-Binding Protein-alpha; CD8-Positive T-Lymphocytes; Cefepime; Cell Differentiation; Cell Line, Tumor; Cell Nucleus; Cell Transdifferentiation; Chelating Agents; Chemical and Drug Induced Liver Injury, Chronic; Chemoradiotherapy, Adjuvant; Child; Child, Preschool; China; Chlorquinaldol; Cholangiocarcinoma; Cholera; Chromatin; Clinical Trials as Topic; Cognitive Dysfunction; Cohort Studies; Colonic Neoplasms; Colorectal Neoplasms; Colorimetry; Cooking; Coordination Complexes; COVID-19; Creatinine; CRISPR-Cas Systems; Critical Care; Critical Illness; Cross-Sectional Studies; Cryopreservation; Cryoprotective Agents; Cysteine; Cytokines; Device Removal; Diet; Diet, High-Fat; Diet, Mediterranean; Dietary Supplements; Dimethyl Sulfoxide; Dipeptides; Disease Models, Animal; Dithiothreitol; DNA; DNA Repeat Expansion; DNA, Bacterial; DNA, Complementary; Dopamine; Electrochemical Techniques; Electrodes; Endocannabinoids; Environmental Exposure; Environmental Monitoring; Environmental Pollutants; Enzyme-Linked Immunosorbent Assay; Erlotinib Hydrochloride; Escherichia coli; Escherichia coli O157; Esophageal Neoplasms; Esophagitis, Peptic; Ethylene Glycol; Europium; Exanthema; Fallopian Tubes; Feces; Female; Fertilization in Vitro; Fluoresceins; Fluorescent Dyes; Follicle Stimulating Hormone; Follow-Up Studies; Food Microbiology; Forced Expiratory Volume; Forkhead Transcription Factors; Frontotemporal Dementia; G-Quadruplexes; Galactose; Gastroenteritis; Gastrointestinal Diseases; Gastrointestinal Microbiome; Gastrointestinal Neoplasms; Gastrointestinal Tract; Gene Frequency; Genetic Association Studies; Genetic Predisposition to Disease; Genital Neoplasms, Female; Genome-Wide Association Study; Genome, Viral; Genomics; Genotype; Glucose; Glutathione; Glycerol; Gold; Graphite; GTPase-Activating Proteins; Heat-Shock Proteins; Heme Oxygenase-1; Hepacivirus; Hepatitis C; Hepatocytes; Histamine; Histocompatibility Antigens Class II; Hoarseness; Hospice and Palliative Care Nursing; Humans; Hydrogen; Hydrogen Peroxide; Hydrogen Sulfide; Hydroxybenzoates; Hydroxyl Radical; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperthermia, Induced; Hysteroscopy; Immunoassay; Indigo Carmine; Inflammation; Inflammatory Bowel Diseases; Insulin Resistance; Intensive Care Units; Interleukin-11; Interleukin-6; Interleukins; Iodine Radioisotopes; Iran; Iridium; Islets of Langerhans; Kinetics; Lactation; Lactobacillus; Lactobacillus plantarum; Lamins; Latin America; Lead; Lectins; Leukopenia; Ligands; Limit of Detection; Lipopolysaccharides; Lipoprotein Lipase; Liver; Liver Cirrhosis; Liver Neoplasms; Lolium; Luminescent Measurements; Luminol; Lung; Luteinizing Hormone; Macrophages; Magnetic Phenomena; Magnetic Resonance Imaging; Male; Malnutrition; Maltose; Manganese Compounds; Maternal Nutritional Physiological Phenomena; Melatonin; Metabolic Engineering; Metal Nanoparticles; Metallocenes; Metaplasia; Methicillin-Resistant Staphylococcus aureus; Methylation; Mevalonic Acid; Mexico; Mice; Mice, Inbred C57BL; Mice, Transgenic; Microbial Sensitivity Tests; Microbiota; MicroRNAs; Milk; Mitomycin; Molecular Diagnostic Techniques; Molecular Docking Simulation; Monte Carlo Method; Moringa oleifera; Multiple Sclerosis; Muscle Strength; Muscle, Skeletal; Nanocomposites; Nanotubes, Carbon; Neoadjuvant Therapy; Neoplasms; Neurodegenerative Diseases; Neurotransmitter Agents; NF-E2-Related Factor 2; Nickel; Nitrogen Dioxide; Non-alcoholic Fatty Liver Disease; Nucleic Acid Amplification Techniques; Nucleic Acid Hybridization; Nucleocapsid Proteins; Nutritional Status; Obesity; Osteogenesis; Osteosarcoma; Oxidation-Reduction; Oxides; Oxygen; Oxyquinoline; Pain; Palliative Care; Pancreatic Neoplasms; Pandemics; Particulate Matter; Peroxidase; Peroxidases; Phagocytosis; Phaseolus; Photothermal Therapy; Point-of-Care Systems; Polyethyleneimine; Polymers; Polymorphism, Single Nucleotide; Polysomnography; Postoperative Complications; Pregnancy; Pregnant Women; Prenatal Exposure Delayed Effects; Prevalence; Printing, Three-Dimensional; Probability; Probiotics; Prognosis; Prophages; Prospective Studies; Proteomics; Proto-Oncogene Proteins; Pseudomonas aeruginosa; Pseudomonas putida; Pulmonary Disease, Chronic Obstructive; Pulmonary Embolism; Pyridines; Pyrroles; Quality of Life; Quinolones; Rabbits; Rats; Rats, Sprague-Dawley; Reactive Oxygen Species; Real-Time Polymerase Chain Reaction; Receptors, Histamine; Receptors, Histamine H2; Recombinases; Rectal Neoplasms; Reperfusion Injury; Respiration; Respiratory Function Tests; Respiratory Rate; Respiratory Sounds; Retrospective Studies; rho GTP-Binding Proteins; Risk Assessment; Risk Factors; RNA; RNA, Messenger; RNA, Ribosomal, 16S; Robotic Surgical Procedures; Running; Rural Population; Saccharomyces cerevisiae; Salpingectomy; Sarcopenia; SARS-CoV-2; Seeds; Semen; Sensitivity and Specificity; Sepsis; Shock, Septic; Signal Transduction; Silicon Dioxide; Silver; Sirtuin 1; Skin Neoplasms; Sleep Apnea, Obstructive; Soil; Spain; Spectrum Analysis, Raman; Sperm Retrieval; Spermatozoa; Spirometry; Staphylococcus aureus; STAT3 Transcription Factor; Stereoisomerism; Sterilization, Tubal; Stroke Volume; Sulfadiazine; Sulfites; Superoxide Dismutase; Surface Plasmon Resonance; tau Proteins; Testis; Testosterone; Thioredoxin-Disulfide Reductase; Thyroid Neoplasms; Thyroidectomy; Trans-Activators; Transcription Factor AP-1; Treatment Outcome; Triazoles; Triclosan; Trifluridine; Tumor Microenvironment; Tumor Necrosis Factor-alpha; United States; Uracil; Vagina; Vegetables; Ventricular Function, Left; Ventricular Pressure; Vibrio cholerae; Vietnam; Virulence; Vital Capacity; Vitrification; Walking; Water; Water Pollutants, Radioactive; Whole Genome Sequencing; Wind; YAP-Signaling Proteins; Zeolites; Zinc Oxide | 2023 |
Bronchodilators for hyperinflation in COPD associated with biomass smoke: clinical trial.
Topics: Administration, Inhalation; Aged; Aged, 80 and over; Biomass; Bronchodilator Agents; Cross-Over Studies; Environmental Exposure; Exercise Test; Female; Forced Expiratory Volume; Humans; Indans; Inspiratory Capacity; Middle Aged; Pulmonary Disease, Chronic Obstructive; Quinolones; Smoke; Spirometry; Tiotropium Bromide; Treatment Outcome; Vital Capacity | 2019 |
Bioequivalence studies of inhaled indacaterol maleate in healthy Chinese volunteers under gastrointestinal non-blocking or blocking with concomitant charcoal administration.
Topics: Administration, Inhalation; Adult; Asian People; Charcoal; Cross-Over Studies; Drug Compounding; Female; Humans; Indans; Male; Maleates; Middle Aged; Pilot Projects; Pulmonary Disease, Chronic Obstructive; Quinolones; Therapeutic Equivalency; Young Adult | 2020 |
Impact of baseline symptoms and health status on COPD exacerbations in the FLAME study.
Topics: Aged; Bronchodilator Agents; Disease Progression; Double-Blind Method; Drug Combinations; Female; Fluticasone-Salmeterol Drug Combination; Forced Expiratory Volume; Glycopyrrolate; Health Status; Humans; Indans; Male; Middle Aged; Pulmonary Disease, Chronic Obstructive; Quinolones; Surveys and Questionnaires | 2020 |
A randomized, controlled, repeat-dose study of batefenterol/fluticasone furoate compared with placebo in the treatment of COPD.
Topics: Administration, Inhalation; Aged; Androstadienes; Carbamates; Double-Blind Method; Drug Combinations; Female; Forced Expiratory Volume; Humans; Male; Middle Aged; Nebulizers and Vaporizers; Pulmonary Disease, Chronic Obstructive; Quinolones; Treatment Outcome | 2020 |
Effectiveness and Tolerability of LABA/LAMA Fixed-Dose Combinations Aclidinium/Formoterol, Glycopyrronium/Indacaterol and Umeclidinium/Vilanterol in the Treatment of COPD in Daily Practice - Results of the Non-Interventional DETECT Study.
Topics: Administration, Inhalation; Adrenergic beta-2 Receptor Agonists; Benzyl Alcohols; Bronchodilator Agents; Chlorobenzenes; Drug Combinations; Formoterol Fumarate; Glycopyrrolate; Humans; Indans; Muscarinic Antagonists; Prospective Studies; Pulmonary Disease, Chronic Obstructive; Quality of Life; Quinolones; Quinuclidines; Treatment Outcome | 2020 |
Long-acting dual bronchodilator therapy (indacaterol/glycopyrronium) versus nebulized short-acting dual bronchodilator (salbutamol/ipratropium) in chronic obstructive pulmonary disease: A double-blind, randomized, placebo-controlled trial.
Topics: Administration, Inhalation; Aged; Albuterol; Bronchodilator Agents; Cross-Over Studies; Delayed-Action Preparations; Double-Blind Method; Drug Combinations; Drug Therapy, Combination; Female; Glycopyrrolate; Humans; Indans; Ipratropium; Male; Metered Dose Inhalers; Middle Aged; Nebulizers and Vaporizers; Pulmonary Disease, Chronic Obstructive; Quinolones; Treatment Outcome | 2020 |
Efficacy and Safety of the CFTR Potentiator Icenticaftor (QBW251) in COPD: Results from a Phase 2 Randomized Trial.
Topics: Aminophenols; Cystic Fibrosis Transmembrane Conductance Regulator; Double-Blind Method; Humans; Mucociliary Clearance; Pulmonary Disease, Chronic Obstructive; Quinolones | 2020 |
[Study of the month : FLAME study in chronic obstructive pulmonary disease].
Topics: Administration, Inhalation; Aged; Bronchodilator Agents; Female; Fluticasone; Forced Expiratory Volume; Glycopyrrolate; Humans; Indans; Male; Middle Aged; Pulmonary Disease, Chronic Obstructive; Quinolones; Salmeterol Xinafoate; Treatment Outcome | 2016 |
Response to Indacaterol/Glycopyrronium (IND/GLY) by Sex in Patients with COPD: A Pooled Analysis from the IGNITE Program.
Topics: Aged; Bronchodilator Agents; Drug Combinations; Dyspnea; Female; Fluticasone-Salmeterol Drug Combination; Forced Expiratory Volume; Glucocorticoids; Glycopyrrolate; Health Status; Humans; Indans; Male; Middle Aged; Muscarinic Antagonists; Pulmonary Disease, Chronic Obstructive; Quinolones; Severity of Illness Index; Sex Factors; Tiotropium Bromide; Vital Capacity | 2017 |
Inhaled indacaterol for the treatment of COPD patients with destroyed lung by tuberculosis and moderate-to-severe airflow limitation: results from the randomized INFINITY study.
Topics: Administration, Inhalation; Adrenergic beta-2 Receptor Agonists; Aged; Bronchodilator Agents; Double-Blind Method; Female; Forced Expiratory Volume; Health Status; Humans; Indans; Lung; Male; Middle Aged; Pulmonary Disease, Chronic Obstructive; Quinolones; Recovery of Function; Republic of Korea; Severity of Illness Index; Time Factors; Treatment Outcome; Tuberculosis, Pulmonary | 2017 |
Efficacy and safety of direct switch to indacaterol/glycopyrronium in patients with moderate COPD: the CRYSTAL open-label randomised trial.
Topics: Adrenergic beta-2 Receptor Agonists; Adult; Aged; Bronchodilator Agents; Disease Progression; Drug Combinations; Drug Substitution; Dyspnea; Europe; Female; Forced Expiratory Volume; Glycopyrrolate; Health Status; Humans; Indans; Lung; Male; Middle Aged; Muscarinic Antagonists; Patient Safety; Prospective Studies; Pulmonary Disease, Chronic Obstructive; Quality of Life; Quinolones; Recovery of Function; Risk Factors; Severity of Illness Index; Time Factors; Treatment Outcome | 2017 |
Dual Bronchodilation with Indacaterol Maleate/Glycopyrronium Bromide Compared with Umeclidinium Bromide/Vilanterol in Patients with Moderate-to-Severe COPD: Results from Two Randomized, Controlled, Cross-over Studies.
Topics: Aged; Benzyl Alcohols; Bronchodilator Agents; Chlorobenzenes; Cross-Over Studies; Double-Blind Method; Drug Combinations; Female; Forced Expiratory Volume; Glycopyrrolate; Humans; Indans; Male; Middle Aged; Muscarinic Antagonists; Pulmonary Disease, Chronic Obstructive; Quinolones; Quinuclidines; Severity of Illness Index | 2017 |
Efficacy of tiotropium and indacaterol monotherapy and their combination on dynamic lung hyperinflation in COPD: a random open-label crossover study.
Topics: Administration, Inhalation; Adrenergic beta-2 Receptor Agonists; Aged; Bronchodilator Agents; Cross-Over Studies; Drug Therapy, Combination; Exercise Tolerance; Female; Forced Expiratory Volume; Humans; Indans; Japan; Lung; Male; Muscarinic Antagonists; Pulmonary Disease, Chronic Obstructive; Quinolones; Recovery of Function; Time Factors; Tiotropium Bromide; Treatment Outcome | 2017 |
Indacaterol/glycopyrronium is cost-effective compared to salmeterol/fluticasone in COPD: FLAME-based modelling in a Swedish population.
Topics: Aged; Cost-Benefit Analysis; Double-Blind Method; Drug Combinations; Female; Fluticasone-Salmeterol Drug Combination; Glycopyrrolate; Humans; Indans; Male; Middle Aged; Models, Economic; Population Surveillance; Pulmonary Disease, Chronic Obstructive; Quinolones; Sweden | 2017 |
Predicting treatable traits for long-acting bronchodilators in patients with stable COPD.
Topics: Adrenergic beta-2 Receptor Agonists; Aged; Bronchodilator Agents; Clinical Decision-Making; Cross-Over Studies; Female; Forced Expiratory Volume; Gene Expression Profiling; Humans; Indans; Lung; Male; Middle Aged; Models, Genetic; Muscarinic Antagonists; Oligonucleotide Array Sequence Analysis; Patient Selection; Precision Medicine; Predictive Value of Tests; Prospective Studies; Pulmonary Disease, Chronic Obstructive; Quantitative Trait, Heritable; Quinolones; Republic of Korea; Time Factors; Tiotropium Bromide; Transcriptome; Treatment Outcome | 2017 |
Extrafine inhaled triple therapy versus dual bronchodilator therapy in chronic obstructive pulmonary disease (TRIBUTE): a double-blind, parallel group, randomised controlled trial.
Topics: Administration, Inhalation; Adrenergic beta-2 Receptor Agonists; Aged; Beclomethasone; Bronchodilator Agents; Double-Blind Method; Drug Therapy, Combination; Female; Formoterol Fumarate; Glucocorticoids; Glycopyrrolate; Humans; Indans; Male; Middle Aged; Muscarinic Antagonists; Pulmonary Disease, Chronic Obstructive; Quinolones | 2018 |
Early Changes in eDiary COPD Symptoms Predict Clinically Relevant Treatment Response at 12 Weeks: Analysis from the CRYSTAL Study.
Topics: Aged; Bronchodilator Agents; Drug Combinations; Dyspnea; Female; Forced Expiratory Volume; Glycopyrrolate; Humans; Indans; Logistic Models; Male; Middle Aged; Multivariate Analysis; Patient Reported Outcome Measures; Prognosis; Pulmonary Disease, Chronic Obstructive; Quinolones; Surveys and Questionnaires; Time Factors; Treatment Outcome | 2018 |
Long-Term Triple Therapy De-escalation to Indacaterol/Glycopyrronium in Patients with Chronic Obstructive Pulmonary Disease (SUNSET): A Randomized, Double-Blind, Triple-Dummy Clinical Trial.
Topics: Administration, Inhalation; Adrenal Cortex Hormones; Aged; Bronchodilator Agents; Double-Blind Method; Female; Fluticasone-Salmeterol Drug Combination; Glucocorticoids; Glycopyrrolate; Humans; Indans; Male; Muscarinic Antagonists; Pulmonary Disease, Chronic Obstructive; Quinolones; Tiotropium Bromide; Treatment Outcome | 2018 |
Indacaterol/glycopyrronium versus salmeterol/fluticasone in the prevention of clinically important deterioration in COPD: results from the FLAME study.
Topics: Aged; Bronchodilator Agents; Disease Progression; Double-Blind Method; Drug Combinations; Female; Fluticasone-Salmeterol Drug Combination; Glycopyrrolate; Humans; Indans; Male; Middle Aged; Pulmonary Disease, Chronic Obstructive; Quinolones | 2018 |
Capturing Exacerbations of Chronic Obstructive Pulmonary Disease with EXACT. A Subanalysis of FLAME.
Topics: Bronchodilator Agents; Disease Progression; Drug Therapy, Combination; Female; Fluticasone; Glycopyrrolate; Humans; Indans; Male; Middle Aged; Pulmonary Disease, Chronic Obstructive; Quinolones; Risk Factors; Salmeterol Xinafoate; Surveys and Questionnaires | 2019 |
Efficacy and safety of the direct switch to indacaterol/glycopyrronium from salmeterol/fluticasone in non-frequently exacerbating COPD patients: The FLASH randomized controlled trial.
Topics: Adrenergic beta-2 Receptor Agonists; Aged; Bronchodilator Agents; Double-Blind Method; Drug Combinations; Drug Monitoring; Drug Substitution; Female; Fluticasone-Salmeterol Drug Combination; Glycopyrrolate; Humans; Indans; Male; Middle Aged; Muscarinic Antagonists; Pulmonary Disease, Chronic Obstructive; Quinolones; Respiratory Function Tests; Treatment Outcome | 2018 |
Treatment response to indacaterol/glycopyrronium versus salmeterol/fluticasone in exacerbating COPD patients by gender: a post-hoc analysis in the FLAME study.
Topics: Aged; Bronchodilator Agents; Disease Progression; Double-Blind Method; Drug Combinations; Female; Fluticasone-Salmeterol Drug Combination; Glycopyrrolate; Humans; Indans; Male; Middle Aged; Pulmonary Disease, Chronic Obstructive; Quinolones; Sex Characteristics; Treatment Outcome | 2019 |
A new class of bronchodilator improves lung function in COPD: a trial with GSK961081.
Topics: Aged; Albuterol; Bronchodilator Agents; Carbamates; Double-Blind Method; Drug Administration Schedule; Female; Forced Expiratory Volume; Humans; Male; Middle Aged; Muscarinic Antagonists; Patient Safety; Pulmonary Disease, Chronic Obstructive; Quinolones; Salmeterol Xinafoate; Smoking; Spirometry; Treatment Outcome | 2013 |
Chronic treatment with indacaterol and airway response to salbutamol in stable COPD.
Topics: Adrenergic beta-2 Receptor Agonists; Aged; Aged, 80 and over; Albuterol; Bronchodilator Agents; Cross-Over Studies; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Ethanolamines; Female; Forced Expiratory Volume; Formoterol Fumarate; Humans; Indans; Male; Middle Aged; Pilot Projects; Pulmonary Disease, Chronic Obstructive; Quinolones; Vital Capacity | 2013 |
Bronchodilation and safety of supratherapeutic doses of salbutamol or ipratropium bromide added to single dose GSK961081 in patients with moderate to severe COPD.
Topics: Aged; Albuterol; Bronchodilator Agents; Carbamates; Cross-Over Studies; Delayed-Action Preparations; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Forced Expiratory Volume; Humans; Ipratropium; Male; Middle Aged; Pulmonary Disease, Chronic Obstructive; Quinolones; Severity of Illness Index; Time Factors; Treatment Outcome | 2013 |
Pharmacodynamics of GSK961081, a bi-functional molecule, in patients with COPD.
Topics: Adrenergic beta-2 Receptor Agonists; Adult; Aged; Albuterol; Bronchodilator Agents; Carbamates; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Forced Expiratory Volume; Humans; Male; Middle Aged; Muscarinic Antagonists; Pulmonary Disease, Chronic Obstructive; Quinolones; Salmeterol Xinafoate; Scopolamine Derivatives; Time Factors; Tiotropium Bromide; Treatment Outcome | 2013 |
The effect of indacaterol during an acute exacerbation of COPD.
Topics: Acute Disease; Administration, Inhalation; Adrenergic beta-2 Receptor Agonists; Aged; Albuterol; Bronchodilator Agents; Drug Therapy, Combination; Hospitalization; Humans; Indans; Ipratropium; Levofloxacin; Male; Methylprednisolone; Nebulizers and Vaporizers; Pilot Projects; Pulmonary Disease, Chronic Obstructive; Quinolones; Treatment Outcome | 2013 |
Safety and efficacy of dual bronchodilation with QVA149 in COPD patients: the ENLIGHTEN study.
Topics: Adrenergic beta-2 Receptor Agonists; Aged; Bronchodilator Agents; Double-Blind Method; Drug Combinations; Female; Forced Expiratory Volume; Glycopyrrolate; Humans; Indans; Male; Medication Adherence; Middle Aged; Muscarinic Antagonists; Pulmonary Disease, Chronic Obstructive; Quinolones; Spirometry; Treatment Outcome; Vital Capacity | 2013 |
Efficacy and safety of QVA149 compared to the concurrent administration of its monocomponents indacaterol and glycopyrronium: the BEACON study.
Topics: Administration, Inhalation; Adrenergic beta-2 Receptor Agonists; Aged; Bronchodilator Agents; Double-Blind Method; Drug Administration Schedule; Drug Combinations; Drug Therapy, Combination; Female; Forced Expiratory Volume; Glycopyrrolate; Humans; Indans; Lung; Male; Middle Aged; Muscarinic Antagonists; Nebulizers and Vaporizers; Pulmonary Disease, Chronic Obstructive; Quinolones; Severity of Illness Index; Time Factors; Treatment Outcome | 2013 |
Dual bronchodilation with QVA149 reduces patient-reported dyspnoea in COPD: the BLAZE study.
Topics: Adult; Aged; Area Under Curve; Bronchodilator Agents; Cross-Over Studies; Drug Combinations; Dyspnea; Female; Forced Expiratory Volume; Glycopyrrolate; Humans; Indans; Male; Middle Aged; Powders; Pulmonary Disease, Chronic Obstructive; Quinolones; Scopolamine Derivatives; Spirometry; Tiotropium Bromide; Treatment Outcome | 2014 |
Effect of indacaterol on arterial blood gases in patients suffering from acute exacerbation of COPD.
Topics: Acute Disease; Administration, Inhalation; Adrenergic beta-2 Receptor Agonists; Aged; Aged, 80 and over; Blood Gas Analysis; Carbon Dioxide; Cross-Over Studies; Female; Forced Expiratory Volume; Humans; Indans; Male; Middle Aged; Oxygen; Partial Pressure; Pulmonary Disease, Chronic Obstructive; Quinolones; Vital Capacity | 2014 |
Combined long-acting bronchodilator single therapy for COPD.
Topics: Bronchodilator Agents; Delayed-Action Preparations; Double-Blind Method; Drug Combinations; Female; Forced Expiratory Volume; Glycopyrrolate; Humans; Indans; Male; Nebulizers and Vaporizers; Pulmonary Disease, Chronic Obstructive; Quinolones | 2014 |
Efficacy and safety of once-daily QVA149 compared with twice-daily salmeterol-fluticasone in patients with chronic obstructive pulmonary disease (ILLUMINATE): a randomised, double-blind, parallel group study.
Topics: Administration, Inhalation; Albuterol; Androstadienes; Bronchodilator Agents; Double-Blind Method; Drug Administration Schedule; Drug Combinations; Female; Fluticasone-Salmeterol Drug Combination; Glucocorticoids; Glycopyrrolate; Humans; Indans; Male; Middle Aged; Pulmonary Disease, Chronic Obstructive; Quinolones; Sympathomimetics; Treatment Outcome | 2013 |
Effect of once-daily indacaterol in a predominantly Chinese population with chronic obstructive pulmonary disease: a 26-week Asia-Pacific study.
Topics: Aged; China; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Follow-Up Studies; Forced Expiratory Volume; Health Status; Humans; Incidence; Indans; Male; Middle Aged; Pulmonary Disease, Chronic Obstructive; Quinolones; Surveys and Questionnaires; Time Factors; Treatment Outcome | 2014 |
Analysis of chronic obstructive pulmonary disease exacerbations with the dual bronchodilator QVA149 compared with glycopyrronium and tiotropium (SPARK): a randomised, double-blind, parallel-group study.
Topics: Administration, Inhalation; Aged; Bronchodilator Agents; Disease Progression; Dose-Response Relationship, Drug; Double-Blind Method; Drug Combinations; Drug Monitoring; Female; Glycopyrrolate; Humans; Indans; Male; Middle Aged; Pulmonary Disease, Chronic Obstructive; Quinolones; Respiratory Function Tests; Respiratory System; Scopolamine Derivatives; Severity of Illness Index; Tiotropium Bromide; Treatment Outcome | 2013 |
Once-daily indacaterol versus tiotropium for patients with severe chronic obstructive pulmonary disease (INVIGORATE): a randomised, blinded, parallel-group study.
Topics: Adult; Aged; Bronchodilator Agents; Double-Blind Method; Drug Administration Schedule; Female; Forced Expiratory Volume; Humans; Indans; Male; Middle Aged; Pulmonary Disease, Chronic Obstructive; Quinolones; Scopolamine Derivatives; Tiotropium Bromide; Treatment Outcome; Vital Capacity | 2013 |
Effect of QVA149 on lung volumes and exercise tolerance in COPD patients: the BRIGHT study.
Topics: Adult; Aged; Bronchodilator Agents; Cross-Over Studies; Double-Blind Method; Drug Administration Schedule; Drug Combinations; Exercise Tolerance; Female; Forced Expiratory Volume; Glycopyrrolate; Humans; Indans; Lung Volume Measurements; Male; Middle Aged; Pulmonary Disease, Chronic Obstructive; Quinolones; Scopolamine Derivatives; Spirometry; Tiotropium Bromide; Treatment Outcome; Vital Capacity | 2014 |
Efficacy and safety of coadministration of once-daily indacaterol and glycopyrronium versus indacaterol alone in COPD patients: the GLOW6 study.
Topics: Administration, Inhalation; Adrenergic beta-2 Receptor Agonists; Aged; Area Under Curve; Bronchodilator Agents; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Europe; Female; Forced Expiratory Volume; Glycopyrrolate; Humans; Indans; Inspiratory Capacity; Lung; Male; Middle Aged; Muscarinic Antagonists; Nebulizers and Vaporizers; Pulmonary Disease, Chronic Obstructive; Quinolones; Severity of Illness Index; Time Factors; Treatment Outcome; Vital Capacity | 2014 |
Computed tomography assessment of airway dimensions with combined tiotropium and indacaterol therapy in COPD patients.
Topics: Administration, Inhalation; Aged; Bronchodilator Agents; Drug Therapy, Combination; Female; Health Status; Humans; Indans; Lung; Male; Middle Aged; Pulmonary Disease, Chronic Obstructive; Quality of Life; Quinolones; Respiratory Function Tests; Scopolamine Derivatives; Severity of Illness Index; Tiotropium Bromide; Tomography, X-Ray Computed; Treatment Outcome | 2014 |
Assessment of acute bronchodilator effects from specific airway resistance changes in stable COPD patients.
Topics: Adrenergic beta-Agonists; Aged; Airway Resistance; Bronchodilator Agents; Cross-Over Studies; Double-Blind Method; Dyspnea; Female; Humans; Indans; Lung Volume Measurements; Male; Plethysmography; Pulmonary Disease, Chronic Obstructive; Quinolones; Respiratory Function Tests; Time Factors; Treatment Outcome | 2014 |
Pooled safety analysis of the fixed-dose combination of indacaterol and glycopyrronium (QVA149), its monocomponents, and tiotropium versus placebo in COPD patients.
Topics: Aged; Bronchodilator Agents; Drug Combinations; Drug Therapy, Combination; Female; Glycopyrrolate; Humans; Indans; Male; Middle Aged; Pulmonary Disease, Chronic Obstructive; Quinolones; Risk Factors; Scopolamine Derivatives; Tiotropium Bromide; Treatment Outcome | 2014 |
Comparison of airway dimensions with once daily tiotropium plus indacaterol versus twice daily Advair(®) in chronic obstructive pulmonary disease.
Topics: Aged; Albuterol; Androstadienes; Bronchodilator Agents; Drug Administration Schedule; Drug Combinations; Drug Therapy, Combination; Female; Fluticasone-Salmeterol Drug Combination; Glucocorticoids; Humans; Indans; Male; Middle Aged; Pulmonary Disease, Chronic Obstructive; Quinolones; Scopolamine Derivatives; Spirometry; Surveys and Questionnaires; Tiotropium Bromide | 2015 |
Once-daily indacaterol 75 μg in moderate- to-severe COPD: results of a Phase IV study assessing time until patients' perceived onset of effect.
Topics: Administration, Inhalation; Adrenergic beta-2 Receptor Agonists; Aged; Bronchodilator Agents; Cross-Over Studies; Double-Blind Method; Drug Administration Schedule; Dry Powder Inhalers; Female; Forced Expiratory Volume; Humans; Indans; Least-Squares Analysis; Lung; Male; Middle Aged; Patients; Perception; Pulmonary Disease, Chronic Obstructive; Quinolones; Severity of Illness Index; Surveys and Questionnaires; Time Factors; Treatment Outcome; United States | 2014 |
Translational Study Searching for Synergy between Glycopyrronium and Indacaterol.
Topics: Administration, Inhalation; Aged; Aged, 80 and over; Bronchi; Bronchodilator Agents; Cross-Over Studies; Dose-Response Relationship, Drug; Drug Synergism; Drug Therapy, Combination; Female; Forced Expiratory Volume; Glycopyrrolate; Humans; Indans; Male; Middle Aged; Pulmonary Disease, Chronic Obstructive; Quinolones; Single-Blind Method; Translational Research, Biomedical; Treatment Outcome | 2015 |
Indacaterol improves lung hyperinflation and physical activity in patients with moderate chronic obstructive pulmonary disease--a randomized, multicenter, double-blind, placebo-controlled study.
Topics: Actigraphy; Aged; Bronchodilator Agents; Cross-Over Studies; Double-Blind Method; Female; Forced Expiratory Volume; Humans; Indans; Inspiratory Capacity; Male; Middle Aged; Motor Activity; Plethysmography, Impedance; Pulmonary Disease, Chronic Obstructive; Quinolones; Scopolamine Derivatives; Spirometry; Tiotropium Bromide | 2014 |
Cost-effectiveness of the LABA/LAMA dual bronchodilator indacaterol/glycopyrronium in a Swedish healthcare setting.
Topics: Aged; Albuterol; Androstadienes; Bronchodilator Agents; Cost-Benefit Analysis; Double-Blind Method; Drug Combinations; Drug Costs; Drug Therapy, Combination; Female; Fluticasone; Forced Expiratory Volume; Glycopyrrolate; Humans; Indans; Male; Middle Aged; Monte Carlo Method; Pulmonary Disease, Chronic Obstructive; Quinolones; Salmeterol Xinafoate; Sweden | 2014 |
INSTEAD: a randomised switch trial of indacaterol versus salmeterol/fluticasone in moderate COPD.
Topics: Administration, Inhalation; Aged; Albuterol; Androstadienes; Bronchodilator Agents; Disease Progression; Double-Blind Method; Drug Combinations; Drug Substitution; Female; Fluticasone-Salmeterol Drug Combination; Forced Expiratory Volume; Glucocorticoids; Humans; Indans; Male; Middle Aged; Pulmonary Disease, Chronic Obstructive; Quinolones; Severity of Illness Index; Treatment Outcome; Vital Capacity | 2014 |
Indacaterol and tiotropium combination therapy in patients with chronic obstructive pulmonary disease.
Topics: Adrenergic beta-2 Receptor Agonists; Aged; Aged, 80 and over; Bronchodilator Agents; Drug Therapy, Combination; Female; Forced Expiratory Volume; Humans; Indans; Male; Middle Aged; Pulmonary Disease, Chronic Obstructive; Quinolones; Respiratory Function Tests; Scopolamine Derivatives; Tiotropium Bromide; Treatment Outcome | 2015 |
Glycopyrronium + indacaterol. A fixed-dose combination with no advantages in COPD.
Topics: Adrenergic beta-2 Receptor Agonists; Double-Blind Method; Drug Therapy, Combination; Glycopyrrolate; Humans; Indans; Muscarinic Antagonists; Pulmonary Disease, Chronic Obstructive; Quinolones | 2014 |
Efficacy and safety of once-daily QVA149 compared with the free combination of once-daily tiotropium plus twice-daily formoterol in patients with moderate-to-severe COPD (QUANTIFY): a randomised, non-inferiority study.
Topics: Adrenergic beta-2 Receptor Agonists; Aged; Bronchodilator Agents; Double-Blind Method; Drug Administration Schedule; Drug Combinations; Ethanolamines; Female; Forced Expiratory Volume; Formoterol Fumarate; Glycopyrrolate; Humans; Indans; Male; Middle Aged; Pulmonary Disease, Chronic Obstructive; Quality of Life; Quinolones; Scopolamine Derivatives; Tiotropium Bromide; Treatment Outcome; Vital Capacity | 2015 |
Influence of indacaterol on daily physical activity in patients with untreated chronic obstructive pulmonary disease.
Topics: Administration, Inhalation; Adrenergic beta-2 Receptor Agonists; Aged; Aged, 80 and over; Bronchodilator Agents; Drug Administration Schedule; Exercise Tolerance; Female; Forced Expiratory Volume; Humans; Indans; Japan; Lung; Male; Motor Activity; Pulmonary Disease, Chronic Obstructive; Quality of Life; Quinolones; Severity of Illness Index; Time Factors; Treatment Outcome | 2015 |
LANTERN: a randomized study of QVA149 versus salmeterol/fluticasone combination in patients with COPD.
Topics: Administration, Inhalation; Adrenergic beta-2 Receptor Agonists; Adult; Aged; Bronchodilator Agents; Double-Blind Method; Drug Combinations; Female; Fluticasone-Salmeterol Drug Combination; Forced Expiratory Volume; Glucocorticoids; Glycopyrrolate; Humans; Indans; Lung; Male; Middle Aged; Muscarinic Antagonists; Nebulizers and Vaporizers; Pulmonary Disease, Chronic Obstructive; Quinolones; Recovery of Function; Severity of Illness Index; Spirometry; Surveys and Questionnaires; Time Factors; Treatment Outcome | 2015 |
Indacaterol vs tiotropium in COPD patients classified as GOLD A and B.
Topics: Bronchodilator Agents; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Forced Expiratory Flow Rates; Humans; Indans; Male; Middle Aged; Prospective Studies; Pulmonary Disease, Chronic Obstructive; Quinolones; Tiotropium Bromide; Treatment Outcome | 2015 |
Effects of indacaterol versus tiotropium on respiratory mechanics assessed by the forced oscillation technique in patients with chronic obstructive pulmonary disease.
Topics: Adrenergic beta-2 Receptor Agonists; Aged; Aged, 80 and over; Airway Resistance; Bronchodilator Agents; Female; Forced Expiratory Volume; Humans; Indans; Japan; Lung; Male; Middle Aged; Muscarinic Antagonists; Oscillometry; Predictive Value of Tests; Pulmonary Disease, Chronic Obstructive; Quinolones; Respiratory Function Tests; Respiratory Mechanics; Time Factors; Tiotropium Bromide; Treatment Outcome; Vital Capacity | 2015 |
FLIGHT1 and FLIGHT2: Efficacy and Safety of QVA149 (Indacaterol/Glycopyrrolate) versus Its Monocomponents and Placebo in Patients with Chronic Obstructive Pulmonary Disease.
Topics: Bronchodilator Agents; Double-Blind Method; Drug Combinations; Drug Therapy, Combination; Female; Glycopyrrolate; Humans; Indans; Male; Middle Aged; Muscarinic Antagonists; Pulmonary Disease, Chronic Obstructive; Quinolones; Severity of Illness Index; Surveys and Questionnaires; Treatment Outcome | 2015 |
Population Pharmacokinetics and Pharmacodynamics of GSK961081 (Batefenterol), a Muscarinic Antagonist and β2-Agonist, in Moderate-to-Severe COPD Patients: Substudy of a Randomized Trial.
Topics: Adrenergic beta-2 Receptor Agonists; Adult; Aged; Carbamates; Dose-Response Relationship, Drug; Double-Blind Method; Female; Forced Expiratory Volume; Humans; Male; Middle Aged; Muscarinic Antagonists; Pulmonary Disease, Chronic Obstructive; Quinolones | 2015 |
[LAMA/LABA or LABA/ICS?].
Topics: Administration, Inhalation; Drug Therapy, Combination; Fluticasone; Forced Expiratory Volume; Glycopyrrolate; Indans; Lung Volume Measurements; Pulmonary Disease, Chronic Obstructive; Quinolones; Salmeterol Xinafoate | 2015 |
Effect of indacaterol on lung deflation improves cardiac performance in hyperinflated COPD patients: an interventional, randomized, double-blind clinical trial.
Topics: Administration, Inhalation; Adrenergic beta-2 Receptor Agonists; Aged; Aged, 80 and over; Airway Resistance; Bronchodilator Agents; Cross-Over Studies; Double-Blind Method; Dyspnea; Echocardiography; Female; Forced Expiratory Volume; Humans; Indans; Inspiratory Capacity; Lung Volume Measurements; Male; Middle Aged; Prospective Studies; Pulmonary Disease, Chronic Obstructive; Quinolones; Treatment Outcome | 2015 |
[LAMA/LABA supports physical activity in COPD patients].
Topics: Drug Combinations; Glycopyrrolate; Humans; Indans; Motor Activity; Pulmonary Disease, Chronic Obstructive; Quinolones | 2016 |
Dual Bronchodilator Therapy with Umeclidinium/Vilanterol Versus Tiotropium plus Indacaterol in Chronic Obstructive Pulmonary Disease: A Randomized Controlled Trial.
Topics: Administration, Inhalation; Adult; Aged; Aged, 80 and over; Benzyl Alcohols; Bronchodilator Agents; Chlorobenzenes; Double-Blind Method; Drug Combinations; Female; Forced Expiratory Volume; Humans; Indans; Male; Middle Aged; Muscarinic Antagonists; Pulmonary Disease, Chronic Obstructive; Quinolones; Quinuclidines; Tiotropium Bromide; Treatment Outcome | 2016 |
Indacaterol-Glycopyrronium versus Salmeterol-Fluticasone for COPD.
Topics: Administration, Inhalation; Adrenergic beta-2 Receptor Agonists; Aged; Double-Blind Method; Drug Combinations; Female; Fluticasone-Salmeterol Drug Combination; Glucocorticoids; Glycopyrrolate; Humans; Indans; Male; Middle Aged; Muscarinic Antagonists; Pulmonary Disease, Chronic Obstructive; Quinolones | 2016 |
Pilot evaluation of ivacaftor for chronic bronchitis.
Topics: Aged; Aminophenols; Bronchitis, Chronic; Chloride Channel Agonists; Cystic Fibrosis Transmembrane Conductance Regulator; Double-Blind Method; Female; Follow-Up Studies; Humans; Male; Middle Aged; Molecular Targeted Therapy; Pilot Projects; Pulmonary Disease, Chronic Obstructive; Quinolones; Risk Assessment; Treatment Outcome | 2016 |
Long-term safety of glycopyrrolate: A randomized study in patients with moderate-to-severe COPD (GEM3).
Topics: Adrenergic beta-2 Receptor Agonists; Aged; Bronchodilator Agents; Double-Blind Method; Electrocardiography; Female; Forced Expiratory Volume; Glycopyrrolate; Humans; Indans; Male; Middle Aged; Muscarinic Antagonists; Pulmonary Disease, Chronic Obstructive; Quinolones; Severity of Illness Index; Treatment Outcome; United States; Vital Capacity; Vital Signs | 2016 |
[Dual bronchodilators becomes the first choice combination].
Topics: Adrenergic beta-2 Receptor Agonists; Double-Blind Method; Drug Combinations; Fluticasone; Glycopyrrolate; Guideline Adherence; Humans; Indans; Muscarinic Antagonists; Pulmonary Disease, Chronic Obstructive; Quinolones; Salmeterol Xinafoate | 2016 |
Effects of indacaterol/glycopyrronium (QVA149) on lung hyperinflation and physical activity in patients with moderate to severe COPD: a randomised, placebo-controlled, crossover study (The MOVE Study).
Topics: Aged; Bronchodilator Agents; Cross-Over Studies; Double-Blind Method; Drug Combinations; Exercise; Female; Forced Expiratory Volume; Germany; Glycopyrrolate; Humans; Indans; Inspiratory Capacity; Male; Middle Aged; Pulmonary Disease, Chronic Obstructive; Quinolones | 2016 |
Efficacy of Double Bronchodilation (LABA+LAMA) in Patients with Chronic Obstructive Pulmonary Disease (COPD) and Lung Cancer.
Topics: Adenocarcinoma; Adrenergic beta-2 Receptor Agonists; Aged; Bronchodilator Agents; Carcinoma, Squamous Cell; Delayed-Action Preparations; Female; Glycopyrrolate; Humans; Indans; Lung Neoplasms; Male; Middle Aged; Muscarinic Antagonists; Pilot Projects; Pneumonectomy; Prospective Studies; Pulmonary Disease, Chronic Obstructive; Quinolones | 2016 |
Abediterol, a novel long-acting β2-agonist: bronchodilation, safety, tolerability and pharmacokinetic results from a single-dose, dose-ranging, active-comparator study in patients with COPD.
Topics: Administration, Inhalation; Adrenergic beta-2 Receptor Agonists; Adult; Aged; Bronchodilator Agents; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind Method; Female; Forced Expiratory Volume; Germany; Humans; Indans; Male; Middle Aged; Pulmonary Disease, Chronic Obstructive; Quinolones; Spirometry; Treatment Outcome | 2016 |
Computed tomography (CT)-assessed bronchodilation induced by inhaled indacaterol and glycopyrronium/indacaterol in COPD.
Topics: Administration, Inhalation; Adrenergic beta-Agonists; Aged; Aged, 80 and over; Bronchi; Bronchodilator Agents; Drug Therapy, Combination; Female; Forced Expiratory Volume; Glycopyrrolate; Humans; Indans; Japan; Lung; Male; Middle Aged; Muscarinic Antagonists; Pulmonary Disease, Chronic Obstructive; Quinolones; Respiratory Function Tests; Tomography, X-Ray Computed | 2016 |
Indacaterol and glycopyrronium versus indacaterol on body plethysmography measurements in COPD-a randomised controlled study.
Topics: Adrenergic beta-2 Receptor Agonists; Adult; Aged; Aged, 80 and over; Cross-Over Studies; Diagnosis, Computer-Assisted; Double-Blind Method; Drug Combinations; Female; Glycopyrrolate; Humans; Indans; Male; Middle Aged; Muscarinic Antagonists; Placebo Effect; Plethysmography, Whole Body; Pulmonary Disease, Chronic Obstructive; Quinolones; Reproducibility of Results; Respiratory Function Tests; Sensitivity and Specificity; Spirometry; Switzerland; Treatment Outcome | 2017 |
Immediate salbutamol responsiveness does not predict long-term benefits of indacaterol in patients with chronic obstructive pulmonary disease.
Topics: Administration, Inhalation; Adrenergic beta-2 Receptor Agonists; Aged; Albuterol; Dose-Response Relationship, Drug; Dyspnea; Female; Forced Expiratory Volume; France; Humans; Indans; Male; Middle Aged; Pulmonary Disease, Chronic Obstructive; Quality of Life; Quinolones; Vital Capacity | 2017 |
Efficacy and safety of indacaterol/glycopyrronium fixed-dose combination in mild-to-moderate COPD patients symptomatic on tiotropium in Korea: study protocol for a randomized controlled trial.
Topics: Administration, Inhalation; Adrenergic beta-2 Receptor Agonists; Bronchodilator Agents; Cholinergic Antagonists; Clinical Protocols; Drug Administration Schedule; Drug Combinations; Drug Substitution; Female; Forced Expiratory Volume; Glycopyrrolate; Humans; Indans; Lung; Male; Pulmonary Disease, Chronic Obstructive; Quinolones; Recovery of Function; Republic of Korea; Research Design; Severity of Illness Index; Spirometry; Time Factors; Tiotropium Bromide; Treatment Outcome; Vital Capacity | 2017 |
Bronchodilator efficacy of indacaterol, a novel once-daily beta2-agonist, in patients with persistent asthma.
Topics: Administration, Inhalation; Adolescent; Adult; Asthma; Bronchodilator Agents; Double-Blind Method; Female; Humans; Indans; Male; Middle Aged; Pulmonary Disease, Chronic Obstructive; Quinolones | 2008 |
24-hour bronchodilator efficacy of single doses of indacaterol in subjects with COPD: comparison with placebo and formoterol.
Topics: Adult; Aged; Area Under Curve; Bronchodilator Agents; Cross-Over Studies; Double-Blind Method; Ethanolamines; Female; Forced Expiratory Volume; Formoterol Fumarate; Humans; Indans; Male; Middle Aged; Placebos; Pulmonary Disease, Chronic Obstructive; Quinolones; Vital Capacity | 2009 |
Bronchodilator effects of indacaterol and formoterol in patients with COPD.
Topics: Adrenergic beta-Agonists; Adult; Aged; Aged, 80 and over; Bronchodilator Agents; Cross-Over Studies; Double-Blind Method; Ethanolamines; Female; Forced Expiratory Volume; Formoterol Fumarate; Humans; Indans; Male; Middle Aged; Pulmonary Disease, Chronic Obstructive; Quinolones; Spirometry; Vital Capacity | 2009 |
Integrating indacaterol dose selection in a clinical study in COPD using an adaptive seamless design.
Topics: Adult; Bronchodilator Agents; Dose-Response Relationship, Drug; Double-Blind Method; Ethanolamines; Female; Formoterol Fumarate; Humans; Indans; Male; Middle Aged; Pulmonary Disease, Chronic Obstructive; Quinolones; Research Design; Respiratory Function Tests; Scopolamine Derivatives; Severity of Illness Index; Tiotropium Bromide | 2010 |
Efficacy and safety of indacaterol 150 microg once-daily in COPD: a double-blind, randomised, 12-week study.
Topics: Adrenergic beta-2 Receptor Agonists; Aged; Double-Blind Method; Female; Humans; Indans; Male; Middle Aged; Patient Satisfaction; Placebos; Pulmonary Disease, Chronic Obstructive; Quinolones; Treatment Outcome | 2010 |
Once-daily bronchodilators for chronic obstructive pulmonary disease: indacaterol versus tiotropium.
Topics: Administration, Inhalation; Blood Glucose; Bronchodilator Agents; Double-Blind Method; Drug Administration Schedule; Dyspnea; Electrocardiography; Female; Forced Expiratory Volume; Health Status; Humans; Indans; Male; Middle Aged; Potassium; Pulmonary Disease, Chronic Obstructive; Quinolones; Scopolamine Derivatives; Spirometry; Tiotropium Bromide | 2010 |
Efficacy of a new once-daily long-acting inhaled beta2-agonist indacaterol versus twice-daily formoterol in COPD.
Topics: Adrenergic beta-Agonists; Aged; Bronchodilator Agents; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Ethanolamines; Female; Forced Expiratory Volume; Formoterol Fumarate; Humans; Indans; Male; Middle Aged; Pulmonary Disease, Chronic Obstructive; Quinolones; Treatment Outcome | 2010 |
Bronchodilator efficacy of single doses of indacaterol in Japanese patients with COPD: A randomised, double-blind, placebo-controlled trial.
Topics: Adrenergic beta-2 Receptor Agonists; Adult; Aged; Bronchodilator Agents; Clinical Protocols; Disease Progression; Double-Blind Method; Female; Humans; Indans; Japan; Male; Middle Aged; Pulmonary Disease, Chronic Obstructive; Quinolones; Respiratory Function Tests | 2010 |
Sustained 24-hour efficacy of once daily indacaterol (300 μg) in patients with chronic obstructive pulmonary disease: a randomized, crossover study.
Topics: Adrenergic beta-2 Receptor Agonists; Aged; Cross-Over Studies; Double-Blind Method; Female; Forced Expiratory Volume; Humans; Indans; Male; Middle Aged; Pulmonary Disease, Chronic Obstructive; Quinolones | 2011 |
Once-daily indacaterol versus twice-daily salmeterol for COPD: a placebo-controlled comparison.
Topics: Adrenal Cortex Hormones; Aged; Albuterol; Bronchodilator Agents; Drug Administration Schedule; Dyspnea; Female; Health Status; Humans; Indans; Male; Middle Aged; Pulmonary Disease, Chronic Obstructive; Quinolones; Respiratory Function Tests; Salmeterol Xinafoate; Smoking; Surveys and Questionnaires | 2011 |
Indacaterol once-daily is equally effective dosed in the evening or morning in COPD.
Topics: Administration, Inhalation; Adrenergic beta-Agonists; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind Method; Forced Expiratory Volume; Humans; Indans; Male; Middle Aged; Pulmonary Disease, Chronic Obstructive; Quinolones; Time Factors | 2010 |
Onset of action of indacaterol in patients with COPD: comparison with salbutamol and salmeterol-fluticasone.
Topics: Adult; Aged; Albuterol; Androstadienes; Bronchodilator Agents; Cross-Over Studies; Female; Fluticasone; Humans; Indans; Male; Middle Aged; Pulmonary Disease, Chronic Obstructive; Quinolones; Salmeterol Xinafoate | 2010 |
Indacaterol provides 24-hour bronchodilation in COPD: a placebo-controlled blinded comparison with tiotropium.
Topics: Administration, Inhalation; Aged; Bronchodilator Agents; Cross-Over Studies; Delayed-Action Preparations; Double-Blind Method; Female; Humans; Indans; Male; Middle Aged; Pulmonary Disease, Chronic Obstructive; Quinolones; Scopolamine Derivatives; Time Factors; Tiotropium Bromide | 2010 |
QVA149 demonstrates superior bronchodilation compared with indacaterol or placebo in patients with chronic obstructive pulmonary disease.
Topics: Aged; Bronchodilator Agents; Dose-Response Relationship, Drug; Drug Combinations; Epidemiologic Methods; Female; Forced Expiratory Volume; Glycopyrrolate; Humans; Indans; Male; Middle Aged; Pulmonary Disease, Chronic Obstructive; Quinolones; Treatment Outcome; Vital Capacity | 2010 |
Cardiovascular safety of QVA149, a combination of Indacaterol and NVA237, in COPD patients.
Topics: Administration, Inhalation; Aged; Atrial Fibrillation; Blood Pressure; Bronchodilator Agents; Dose-Response Relationship, Drug; Double-Blind Method; Drug Combinations; Electrocardiography, Ambulatory; Female; Glycopyrrolate; Heart Rate; Humans; Hyperkalemia; Indans; Male; Middle Aged; Pulmonary Disease, Chronic Obstructive; Quinolones; Tachycardia, Ventricular | 2010 |
Efficacy, safety and pharmacokinetics of indacaterol in Caucasian and Japanese patients with chronic obstructive pulmonary disease: a comparison of data from two randomized, placebo-controlled studies.
Topics: Adrenergic beta-2 Receptor Agonists; Aged; Asian People; Female; Humans; Indans; Male; Middle Aged; Pulmonary Disease, Chronic Obstructive; Quinolones; White People | 2011 |
Long-term safety and efficacy of indacaterol, a long-acting β₂-agonist, in subjects with COPD: a randomized, placebo-controlled study.
Topics: Administration, Inhalation; Administration, Oral; Bronchoconstriction; Delayed-Action Preparations; Dose-Response Relationship, Drug; Double-Blind Method; Female; Follow-Up Studies; Forced Expiratory Flow Rates; Humans; Indans; Male; Middle Aged; Pulmonary Disease, Chronic Obstructive; Quinolones; Remission Induction; Time Factors; Treatment Outcome | 2011 |
Indacaterol once-daily provides superior efficacy to salmeterol twice-daily in COPD: a 12-week study.
Topics: Albuterol; Bronchodilator Agents; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Forced Expiratory Volume; Humans; Indans; Male; Middle Aged; Pulmonary Disease, Chronic Obstructive; Quinolones; Respiratory Function Tests; Salmeterol Xinafoate; Treatment Outcome | 2011 |
Profiling the effects of indacaterol on dyspnoea and health status in patients with COPD.
Topics: Adrenergic beta-2 Receptor Agonists; Aged; Albuterol; Double-Blind Method; Dyspnea; Ethanolamines; Female; Forced Expiratory Volume; Formoterol Fumarate; Health Status; Humans; Indans; Male; Middle Aged; Pulmonary Disease, Chronic Obstructive; Quinolones; Salmeterol Xinafoate | 2011 |
Effect of indacaterol on exercise endurance and lung hyperinflation in COPD.
Topics: Bronchodilator Agents; Cross-Over Studies; Double-Blind Method; Exercise Test; Exercise Tolerance; Female; Forced Expiratory Volume; Humans; Indans; Lung; Male; Middle Aged; Pulmonary Disease, Chronic Obstructive; Quinolones; Respiratory Function Tests; Rest | 2011 |
Blinded 12-week comparison of once-daily indacaterol and tiotropium in COPD.
Topics: Adrenergic beta-2 Receptor Antagonists; Aged; Bronchodilator Agents; Cholinergic Antagonists; Double-Blind Method; Drug Administration Schedule; Female; Forced Expiratory Volume; Humans; Indans; Male; Medical Records; Middle Aged; Pulmonary Disease, Chronic Obstructive; Quinolones; Scopolamine Derivatives; Severity of Illness Index; Spirometry; Tiotropium Bromide; Treatment Outcome | 2011 |
Delivery characteristics and patients' handling of two single-dose dry-powder inhalers used in COPD.
Topics: Administration, Inhalation; Adrenergic beta-2 Receptor Agonists; Adult; Aerosols; Aged; Bronchodilator Agents; Canada; Cholinergic Antagonists; Cross-Over Studies; Dry Powder Inhalers; Equipment Design; Female; Humans; Indans; Inhalation; Lung; Male; Middle Aged; Particle Size; Patient Education as Topic; Patient Preference; Pulmonary Disease, Chronic Obstructive; Quinolones; Scopolamine Derivatives; Severity of Illness Index; Surveys and Questionnaires; Time Factors; Tiotropium Bromide; Treatment Outcome; United States | 2011 |
Application of latent growth and growth mixture modeling to identify and characterize differential responders to treatment for COPD.
Topics: Administration, Inhalation; Albuterol; Bronchodilator Agents; Delayed-Action Preparations; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Ethanolamines; Female; Follow-Up Studies; Forced Expiratory Volume; Formoterol Fumarate; Humans; Indans; Male; Middle Aged; Pulmonary Disease, Chronic Obstructive; Quinolones; Salmeterol Xinafoate; Scopolamine Derivatives; Surveys and Questionnaires; Time Factors; Tiotropium Bromide; Treatment Outcome | 2011 |
Effect of indacaterol on dynamic lung hyperinflation and breathlessness in hyperinflated patients with COPD.
Topics: Adrenergic beta-2 Receptor Agonists; Aged; Cross-Over Studies; Double-Blind Method; Dyspnea; Exercise Tolerance; Female; Forced Expiratory Volume; Humans; Indans; Inspiratory Capacity; Linear Models; Male; Middle Aged; Pulmonary Disease, Chronic Obstructive; Quinolones; Treatment Outcome | 2011 |
Acute effects of indacaterol on lung hyperinflation in moderate COPD: a comparison with tiotropium.
Topics: Aged; Area Under Curve; Bronchodilator Agents; Cross-Over Studies; Dose-Response Relationship, Drug; Female; Forced Expiratory Volume; Humans; Indans; Inspiratory Capacity; Lung Volume Measurements; Male; Pulmonary Disease, Chronic Obstructive; Quinolones; Scopolamine Derivatives; Severity of Illness Index; Spirometry; Time Factors; Tiotropium Bromide; Vital Capacity | 2012 |
Efficacy and safety of indacaterol 150 and 300 µg in chronic obstructive pulmonary disease patients from six Asian areas including Japan: a 12-week, placebo-controlled study.
Topics: Administration, Inhalation; Adult; Aged; Bronchoconstriction; Dose-Response Relationship, Drug; Double-Blind Method; Female; Follow-Up Studies; Forced Expiratory Volume; Hong Kong; Humans; Indans; India; Japan; Male; Middle Aged; Prevalence; Pulmonary Disease, Chronic Obstructive; Quinolones; Republic of Korea; Retrospective Studies; Singapore; Surveys and Questionnaires; Taiwan; Time Factors; Treatment Outcome | 2012 |
A pharmacogenetic study of ADRB2 polymorphisms and indacaterol response in COPD patients.
Topics: Adrenergic beta-2 Receptor Agonists; Adult; Aged; Double-Blind Method; Female; Genotype; Humans; Indans; Linkage Disequilibrium; Male; Middle Aged; Pharmacogenetics; Polymorphism, Genetic; Pulmonary Disease, Chronic Obstructive; Quinolones; Receptors, Adrenergic, beta-2; Retrospective Studies | 2012 |
Efficacy and tolerability of indacaterol 75 μg once daily in patients aged ≥40 years with chronic obstructive pulmonary disease: results from 2 double-blind, placebo-controlled 12-week studies.
Topics: Adrenergic beta-2 Receptor Agonists; Adult; Aged; Albuterol; Analysis of Variance; Bronchodilator Agents; Double-Blind Method; Drug Administration Schedule; Female; Forced Expiratory Volume; Humans; Indans; Lung; Male; Middle Aged; Placebos; Pulmonary Disease, Chronic Obstructive; Quinolones; Severity of Illness Index; Spirometry; Surveys and Questionnaires; Time Factors; Treatment Outcome; United States | 2011 |
Concurrent use of indacaterol plus tiotropium in patients with COPD provides superior bronchodilation compared with tiotropium alone: a randomised, double-blind comparison.
Topics: Adrenergic beta-Agonists; Adult; Analysis of Variance; Area Under Curve; Bronchodilator Agents; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Indans; Least-Squares Analysis; Male; Middle Aged; Placebos; Pulmonary Disease, Chronic Obstructive; Quinolones; Respiratory Function Tests; Scopolamine Derivatives; Severity of Illness Index; Tiotropium Bromide; Treatment Outcome | 2012 |
Indacaterol add-on therapy improves lung function, exercise capacity and life quality of COPD patients.
Topics: Adrenergic beta-2 Receptor Agonists; Aged; Bronchodilator Agents; Dyspnea; Exercise; Exercise Tolerance; Female; Forced Expiratory Volume; Humans; Indans; Lung; Male; Middle Aged; Muscarinic Antagonists; Pulmonary Disease, Chronic Obstructive; Pulmonary Ventilation; Quality of Life; Quinolones; Receptors, Adrenergic, beta-2; Respiratory Function Tests; Surveys and Questionnaires | 2013 |
Efficacy of indacaterol 75 μg once-daily on dyspnea and health status: results of two double-blind, placebo-controlled 12-week studies.
Topics: Administration, Inhalation; Adrenergic beta-2 Receptor Agonists; Aged; Analysis of Variance; Double-Blind Method; Drug Administration Schedule; Dyspnea; Female; Forced Expiratory Volume; Health Status Indicators; Humans; Indans; Logistic Models; Male; Middle Aged; Pulmonary Disease, Chronic Obstructive; Quinolones; Surveys and Questionnaires; Treatment Outcome | 2012 |
Assessing efficacy of indacaterol in moderate and severe COPD patients: a 12-week study in an Asian population.
Topics: Adult; Aged; Asia; Bronchodilator Agents; Double-Blind Method; Dyspnea; Female; Forced Expiratory Volume; Health Status; Humans; Indans; Male; Middle Aged; Pulmonary Disease, Chronic Obstructive; Quinolones; Sleep Wake Disorders; Treatment Outcome; Vital Capacity | 2012 |
Effect of an additional dose of indacaterol in COPD patients under regular treatment with indacaterol.
Topics: Administration, Inhalation; Adrenergic beta-2 Receptor Agonists; Aged; Bronchodilator Agents; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Forced Expiratory Volume; Heart Rate; Humans; Indans; Male; Middle Aged; Oxygen; Pilot Projects; Pulmonary Disease, Chronic Obstructive; Quinolones; Treatment Outcome; Vital Capacity | 2013 |
Indacaterol improves daily physical activity in patients with chronic obstructive pulmonary disease.
Topics: Accelerometry; Adrenergic beta-2 Receptor Agonists; Aged; Bronchodilator Agents; Exercise Test; Female; Forced Expiratory Volume; Humans; Indans; Male; Motor Activity; Pulmonary Disease, Chronic Obstructive; Quinolones | 2013 |
Safety, tolerability and efficacy of indacaterol, a novel once-daily beta(2)-agonist, in patients with COPD: a 28-day randomised, placebo controlled clinical trial.
Topics: Administration, Inhalation; Adrenergic beta-Agonists; Adult; Aged; Blood Glucose; Blood Pressure; Dose-Response Relationship, Drug; Double-Blind Method; Electrocardiography; Female; Follow-Up Studies; Forced Expiratory Volume; Heart Rate; Humans; Indans; Male; Middle Aged; Nebulizers and Vaporizers; Potassium; Pulmonary Disease, Chronic Obstructive; Quinolones; Severity of Illness Index; Time Factors | 2007 |
A dose-ranging study of indacaterol in obstructive airways disease, with a tiotropium comparison.
Topics: Administration, Inhalation; Adult; Aged; Bronchodilator Agents; Dose-Response Relationship, Drug; Double-Blind Method; Female; Forced Expiratory Volume; Humans; Indans; Male; Middle Aged; Pulmonary Disease, Chronic Obstructive; Quinolones; Scopolamine Derivatives; Tiotropium Bromide; Treatment Outcome | 2008 |
106 other study(ies) available for carbostyril and Pulmonary Disease, Chronic Obstructive
| Article | Year |
|---|---|
Real-world Safety and Efficacy of Indacaterol/Glycopyrronium in Japanese Patients with Chronic Obstructive Pulmonary Disease: A 52-week Post-marketing Surveillance.
Topics: Adrenergic beta-2 Receptor Agonists; Aged; Bronchodilator Agents; Drug Combinations; Forced Expiratory Volume; Glycopyrrolate; Humans; Indans; Japan; Muscarinic Antagonists; Product Surveillance, Postmarketing; Pulmonary Disease, Chronic Obstructive; Quinolones; Treatment Outcome | 2022 |
[Fixed combination of mometasone, indacaterol, glycopyrronium for the treatment of severe asthma : Enerzair® Breezhaler®].
Topics: Administration, Inhalation; Asthma; Glycopyrrolate; Humans; Indans; Mometasone Furoate; Pulmonary Disease, Chronic Obstructive; Quinolones | 2021 |
Comparing Clinical Outcomes of Tiotropium/Olodaterol, Umeclidinium/Vilanterol, and Indacaterol/Glycopyrronium Fixed-Dose Combination Therapy in Patients with Chronic Obstructive Pulmonary Disease in Taiwan: A Multicenter Cohort Study.
Topics: Adrenergic beta-2 Receptor Agonists; Benzoxazines; Benzyl Alcohols; Bronchodilator Agents; Chlorobenzenes; Drug Combinations; Glycopyrrolate; Humans; Indans; Muscarinic Antagonists; Pulmonary Disease, Chronic Obstructive; Quinolones; Quinuclidines; Retrospective Studies; Taiwan; Tiotropium Bromide; Treatment Outcome | 2022 |
One bronchodilator or two? Translating clinical trials into clinical practice.
Topics: Bronchodilator Agents; Glycopyrrolate; Humans; Indans; Pulmonary Disease, Chronic Obstructive; Quinolones; Tiotropium Bromide | 2020 |
Dual use of bronchodilators versus monotherapy, and its impact on pulmonary rehabilitation in COPD patients.
Topics: Adrenergic beta-2 Receptor Agonists; Aged; Aged, 80 and over; Bronchodilator Agents; Drug Therapy, Combination; Female; Glycopyrrolate; Humans; Indans; Male; Middle Aged; Muscarinic Antagonists; Prospective Studies; Pulmonary Disease, Chronic Obstructive; Quinolones; Tiotropium Bromide | 2020 |
COPD clinical control as a predictor of future exacerbations: concept validation in the SPARK study population.
Topics: Aged; Bronchodilator Agents; Disease Progression; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Glycopyrrolate; Humans; Indans; Male; Middle Aged; Prospective Studies; Pulmonary Disease, Chronic Obstructive; Quinolones; Reproducibility of Results; Respiratory Function Tests; Risk Assessment; Severity of Illness Index; Tiotropium Bromide; Treatment Outcome | 2020 |
Modelling the Cost-Effectiveness of Indacaterol/Glycopyrronium versus Salmeterol/Fluticasone Using a Novel Markov Exacerbation-Based Approach.
Topics: Bronchodilator Agents; Cost-Benefit Analysis; Drug Combinations; Fluticasone-Salmeterol Drug Combination; Glycopyrrolate; Humans; Indans; Markov Chains; Pulmonary Disease, Chronic Obstructive; Quinolones; Sweden; Treatment Outcome | 2020 |
[The concept of chronic obstructive pulmonary disease clinical control as a decision - making tool in real clinical practice for optimizing of basic pharmacotherapy].
Topics: Administration, Inhalation; Adrenergic beta-2 Receptor Agonists; Bronchodilator Agents; Humans; Indans; Pulmonary Disease, Chronic Obstructive; Quinolones | 2020 |
Evidence of Small Airways Disease and the Immediate Effects of Lumacaftor/Ivacaftor in Children with Cystic Fibrosis.
Topics: Adolescent; Airway Remodeling; Aminophenols; Aminopyridines; Benzodioxoles; Child; Cystic Fibrosis; Drug Combinations; Female; Forced Expiratory Volume; Humans; Male; Negative Results; Pulmonary Disease, Chronic Obstructive; Quinolones; Retrospective Studies; Risk Factors | 2020 |
Association of US Food and Drug Administration Removal of Indications for Use of Oral Quinolones With Prescribing Trends.
Topics: Anti-Bacterial Agents; Drug Prescriptions; Humans; Interrupted Time Series Analysis; Practice Patterns, Physicians'; Pulmonary Disease, Chronic Obstructive; Quinolones; Sinusitis; United States; United States Food and Drug Administration; Urinary Tract Infections | 2021 |
Comparative Effectiveness and Safety of Different Types of Inhaled Long-Acting β
Topics: Administration, Inhalation; Adrenergic beta-2 Receptor Agonists; Aged; Beclomethasone; Benzyl Alcohols; Budesonide, Formoterol Fumarate Drug Combination; Chlorobenzenes; Cohort Studies; Comparative Effectiveness Research; Disease Progression; Drug Combinations; Female; Fluticasone-Salmeterol Drug Combination; Formoterol Fumarate; Glucocorticoids; Glycopyrrolate; Humans; Indans; Male; Muscarinic Antagonists; Pneumonia; Propensity Score; Proportional Hazards Models; Pulmonary Disease, Chronic Obstructive; Quinolones; Quinuclidines | 2021 |
Effects of indacaterol on the LPS-evoked changes in fluid secretion rate and pH in swine tracheal membrane.
Topics: Acetylcholine; Adrenergic beta-2 Receptor Agonists; Animals; Bicarbonates; Bronchodilator Agents; Cell Line, Tumor; Cells, Cultured; Cystic Fibrosis Transmembrane Conductance Regulator; Glycopyrrolate; Humans; Hydrogen-Ion Concentration; Indans; Lipopolysaccharides; Mucins; Muscarinic Antagonists; Pulmonary Disease, Chronic Obstructive; Quinolones; Respiratory Mucosa; Swine; Trachea | 2021 |
In COPD, prophylactic macrolides, but not tetracyclines or quinolones, reduce exacerbations, with fewer serious adverse events.
Topics: Adult; Anti-Bacterial Agents; Antibiotic Prophylaxis; Disease Progression; Humans; Macrolides; Pulmonary Disease, Chronic Obstructive; Quinolones; Tetracyclines | 2021 |
Effects of (a Combination of) the Beta
Topics: Adrenergic beta-2 Receptor Agonists; Animals; Bronchoconstriction; Bronchodilator Agents; Case-Control Studies; Dose-Response Relationship, Drug; Drug Synergism; Drug Therapy, Combination; Female; Glycopyrrolate; Guinea Pigs; Humans; Indans; Lung; Male; Muscarinic Antagonists; Pulmonary Disease, Chronic Obstructive; Quinolones; Receptor, Muscarinic M3; Receptors, Adrenergic, beta-2 | 2021 |
Cost-Utility Analysis of Fixed-Dose Combination of Indacaterol Acetate Glycopyrronium Bromide and Mometasone Furoate as a Maintenance Treatment in Adult Patients with Asthma Not Adequately Controlled with a Maintenance Combination of a Long-Acting Beta-Ag
Topics: Acetates; Adrenal Cortex Hormones; Adult; Asthma; Bronchodilator Agents; Cost-Benefit Analysis; Drug Combinations; Glycopyrrolate; Humans; Indans; Mometasone Furoate; Pulmonary Disease, Chronic Obstructive; Quality of Life; Quinolones; Treatment Outcome | 2021 |
Two cases of chronic obstructive pulmonary disease evaluated by dynamic-ventilatory digital radiography for pulmonary function and assessment of treatment efficacy.
Topics: Aged; Asthma; Bronchodilator Agents; Drug Combinations; Fluticasone; Formoterol Fumarate; Glycopyrrolate; Humans; Indans; Lung; Male; Middle Aged; Pulmonary Disease, Chronic Obstructive; Quinolones; Radiographic Image Enhancement; Radiography, Thoracic; Spirometry; Tiotropium Bromide; Treatment Outcome | 2021 |
Efficacy and safety of indacaterol in patients with chronic obstructive pulmonary disease aged over 65 years: A pooled analysis.
Topics: Adrenergic beta-2 Receptor Agonists; Aged; Aged, 80 and over; Bronchodilator Agents; Clinical Trials, Phase III as Topic; Double-Blind Method; Dyspnea; Female; Forced Expiratory Volume; Formoterol Fumarate; Health Status; Humans; Indans; Male; Middle Aged; Netherlands; Prevalence; Prospective Studies; Pulmonary Disease, Chronic Obstructive; Quinolones; Randomized Controlled Trials as Topic; Salmeterol Xinafoate; Severity of Illness Index; Smoking; Tiotropium Bromide; Treatment Outcome; Vital Capacity | 2017 |
GOLD 2017 treatment pathways in 'real life': An analysis of the DACCORD observational study.
Topics: Administration, Inhalation; Adrenal Cortex Hormones; Adrenergic beta-2 Receptor Agonists; Aged; Critical Pathways; Disease Management; Disease Progression; Drug Combinations; Drug Therapy, Combination; Female; Germany; Glycopyrrolate; Humans; Indans; Longitudinal Studies; Maintenance Chemotherapy; Male; Middle Aged; Muscarinic Antagonists; Practice Guidelines as Topic; Prospective Studies; Pulmonary Disease, Chronic Obstructive; Quinolones | 2017 |
[Evaluation of effect of indacaterol (Onbrez) and/or glycopyrronium (Seebri) treatment on Quality of Life of COPD patients in medical practice in Poland - observational study (OSQO)].
Topics: Aged; Drug Therapy, Combination; Female; Glycopyrrolate; Humans; Indans; Male; Middle Aged; Poland; Pulmonary Disease, Chronic Obstructive; Quality of Life; Quinolones; Treatment Outcome | 2017 |
Relationship between lung function and inhalation devices for LAMA/LABA therapy for chronic obstructive pulmonary disease.
Topics: Adrenergic beta-2 Receptor Agonists; Aged; Aged, 80 and over; Benzoxazines; Delayed-Action Preparations; Drug Combinations; Dry Powder Inhalers; Forced Expiratory Volume; Glycopyrrolate; Humans; Indans; Male; Muscarinic Antagonists; Pulmonary Disease, Chronic Obstructive; Quinolones; Tiotropium Bromide; Vital Capacity | 2018 |
Cost-effectiveness of indacaterol/glycopyrronium in comparison with salmeterol/fluticasone combination for patients with moderate-to-severe chronic obstructive pulmonary disease: a LANTERN population analysis from Singapore.
Topics: Aged; Bronchodilator Agents; Cohort Studies; Computer Simulation; Cost-Benefit Analysis; Drug Combinations; Drug Costs; Female; Fluticasone-Salmeterol Drug Combination; Forced Expiratory Volume; Glycopyrrolate; Hospitals; Humans; Indans; Male; Middle Aged; Probability; Pulmonary Disease, Chronic Obstructive; Quality-Adjusted Life Years; Quinolones; Singapore | 2018 |
DNA damage protection by bulk and nano forms of quercetin in lymphocytes of patients with chronic obstructive pulmonary disease exposed to the food mutagen 2-amino-3-methylimidazo [4,5-f]quinolone (IQ).
Topics: Catalase; Comet Assay; DNA Damage; Humans; Lymphocytes; Micronucleus Tests; Mutagens; Oxidative Stress; Pulmonary Disease, Chronic Obstructive; Quercetin; Quinolones | 2018 |
To Withdraw or Not to Withdraw Inhaled Corticosteroids from Triple Therapy in Chronic Obstructive Pulmonary Disease.
Topics: Adrenal Cortex Hormones; Double-Blind Method; Humans; Indans; Pulmonary Disease, Chronic Obstructive; Quinolones | 2018 |
Double combination inhalers in COPD: How to get your head around this data.
Topics: Fluticasone; Humans; Indans; Nebulizers and Vaporizers; Pulmonary Disease, Chronic Obstructive; Quinolones; Salmeterol Xinafoate | 2018 |
Different Background, Short Duration, and Inappropriate Participants May Harm Your Conclusion.
Topics: Double-Blind Method; Humans; Indans; Pulmonary Disease, Chronic Obstructive; Quinolones | 2019 |
Reply to Lan and Shi: Different Background, Short Duration, and Inappropriate Participants May Harm Your Conclusion.
Topics: Double-Blind Method; Humans; Indans; Pulmonary Disease, Chronic Obstructive; Quinolones | 2019 |
Indacaterol/Glycopyrronium versus Salmeterol/Fluticasone in Patients with COPD-A Cost-Effectiveness Analysis in the Czech Republic.
Topics: Bronchodilator Agents; Cost-Benefit Analysis; Czech Republic; Female; Fluticasone-Salmeterol Drug Combination; Glycopyrrolate; Humans; Indans; Male; Muscarinic Antagonists; Pulmonary Disease, Chronic Obstructive; Quality-Adjusted Life Years; Quinolones | 2018 |
Morbidity and mortality in a population of patients affected by heart failure and chronic obstructive pulmonary disease: an observational study.
Topics: Adrenergic beta-2 Receptor Agonists; Aged; Aged, 80 and over; Bronchodilator Agents; Comorbidity; Drug Combinations; Female; Glycopyrrolate; Heart Failure; Heart Ventricles; Humans; Indans; Italy; Lung; Male; Middle Aged; Muscarinic Antagonists; Patient Readmission; Pulmonary Disease, Chronic Obstructive; Quinolones; Recovery of Function; Retrospective Studies; Risk Factors; Time Factors; Treatment Outcome | 2019 |
On Trapped Air and Trapped Blood in Chronic Obstructive Pulmonary Disease.
Topics: Cross-Over Studies; Double-Blind Method; Humans; Indans; Lung; Pulmonary Disease, Chronic Obstructive; Quinolones | 2019 |
Improvement in health status with once-daily indacaterol/glycopyrronium 110/50 μg in COPD patients: real-world evidence from an observational study in Ireland.
Topics: Adrenergic beta-2 Receptor Agonists; Adult; Aged; Aged, 80 and over; Bronchodilator Agents; Drug Combinations; Female; Glycopyrrolate; Health Status; Humans; Indans; Ireland; Male; Middle Aged; Muscarinic Antagonists; Prospective Studies; Pulmonary Disease, Chronic Obstructive; Quinolones; Severity of Illness Index; Surveys and Questionnaires; Treatment Outcome | 2019 |
Use of inspiratory profiles from patients with chronic obstructive pulmonary disease (COPD) to investigate drug delivery uniformity and aerodynamic dose emission of indacaterol from a capsule based dry powder inhaler.
Topics: Administration, Inhalation; Aged; Drug Delivery Systems; Dry Powder Inhalers; Female; Humans; Indans; Inspiratory Capacity; Lung; Male; Middle Aged; Outcome Assessment, Health Care; Powders; Pulmonary Disease, Chronic Obstructive; Quinolones; Respiratory Therapy | 2019 |
Effect of smoking status on lung function, patient-reported outcomes, and safety among patients with COPD treated with indacaterol/glycopyrrolate: Pooled analysis of the FLIGHT1 and FLIGHT2 studies.
Topics: Adult; Aged; Aged, 80 and over; Drug Therapy, Combination; Female; Glycopyrrolate; Humans; Indans; Lung; Male; Middle Aged; Pulmonary Disease, Chronic Obstructive; Quinolones; Safety; Smoking; Treatment Outcome | 2019 |
Phenotypic and genetic characterization of Pseudomonas aeruginosa isolate COP2 from the lungs of COPD patients in China.
Topics: Biofilms; China; Drug Resistance, Bacterial; Humans; Locomotion; Lung; Mutation; Pseudomonas aeruginosa; Pseudomonas Infections; Pulmonary Disease, Chronic Obstructive; Quinolones; Sputum; Transcriptome; Virulence; Whole Genome Sequencing | 2019 |
Efficacy and safety of indacaterol and tiotropium in COPD patients according to dyspnoea severity.
Topics: Bronchodilator Agents; Delayed-Action Preparations; Dose-Response Relationship, Drug; Dyspnea; Forced Expiratory Volume; Humans; Indans; Patient Acuity; Pulmonary Disease, Chronic Obstructive; Quinolones; Randomized Controlled Trials as Topic; Scopolamine Derivatives; Tiotropium Bromide | 2013 |
A UK-based cost-utility analysis of indacaterol, a once-daily maintenance bronchodilator for patients with COPD, using real world evidence on resource use.
Topics: Aged; Albuterol; Bronchodilator Agents; Cost-Benefit Analysis; Drug Administration Schedule; Drug Costs; Female; Humans; Indans; Male; Markov Chains; Middle Aged; Models, Economic; Pulmonary Disease, Chronic Obstructive; Quinolones; Salmeterol Xinafoate; Scopolamine Derivatives; Tiotropium Bromide; Treatment Outcome; United Kingdom | 2013 |
Indacaterol-induced severe constipation and abdominal pain: is there a role for colonic β3-adrenoceptors?
Topics: Abdominal Pain; Adrenergic beta-2 Receptor Agonists; Aged; Bronchodilator Agents; Colon; Constipation; Humans; Indans; Male; Muscle, Smooth; Pulmonary Disease, Chronic Obstructive; Quinolones; Receptors, Adrenergic | 2013 |
Pipeline for COPD drugs flows with combination candidates.
Topics: Bronchodilator Agents; Drug Combinations; Glycopyrrolate; Humans; Indans; Pulmonary Disease, Chronic Obstructive; Quinolones | 2013 |
The MABA approach: a new option to improve bronchodilator therapy.
Topics: Bronchodilator Agents; Carbamates; Female; Humans; Male; Pulmonary Disease, Chronic Obstructive; Quinolones | 2013 |
Future of fixed-dose longacting β2-agonist and antimuscarinic combination therapy in COPD.
Topics: Albuterol; Androstadienes; Bronchodilator Agents; Drug Combinations; Female; Fluticasone-Salmeterol Drug Combination; Glucocorticoids; Glycopyrrolate; Humans; Indans; Male; Pulmonary Disease, Chronic Obstructive; Quinolones; Sympathomimetics | 2013 |
Indacaterol therapy in moderate-to-severe chronic obstructive pulmonary disease: findings from a single-center primary care cohort.
Topics: Adrenergic beta-2 Receptor Agonists; Aged; Bronchodilator Agents; Drug Substitution; Drug Therapy, Combination; Drug Utilization Review; Dyspnea; England; Exercise Tolerance; Female; Forced Expiratory Volume; Humans; Indans; Lung; Male; Medical Audit; Middle Aged; Muscarinic Antagonists; Primary Health Care; Pulmonary Disease, Chronic Obstructive; Quality of Life; Quinolones; Retrospective Studies; Severity of Illness Index; Surveys and Questionnaires; Time Factors; Treatment Outcome | 2013 |
Ask the doctor. My husband was just diagnosed with COPD. Are there any new treatments he can get for it?
Topics: Administration, Inhalation; Dose-Response Relationship, Drug; Female; Humans; Indans; Male; Pulmonary Disease, Chronic Obstructive; Quinolones; Respiratory Function Tests | 2013 |
COPD treatment: time to change our algorithm?
Topics: Drug Combinations; Female; Glycopyrrolate; Humans; Indans; Male; Pulmonary Disease, Chronic Obstructive; Quinolones; Respiratory System; Scopolamine Derivatives; Tiotropium Bromide | 2013 |
2013 American Thoracic Society International Conference.
Topics: alpha 1-Antitrypsin; alpha 1-Antitrypsin Deficiency; Analgesics, Non-Narcotic; Asthma; Benzamides; Clofazimine; Congresses as Topic; Cyclobutanes; Drug Combinations; Glycopyrrolate; Hospital Mortality; Humans; Indans; Intensive Care Units; Lung; Pulmonary Disease, Chronic Obstructive; Quinolones; Societies, Medical; Thoracic Diseases; Treatment Outcome; Tuberculosis, Multidrug-Resistant; United States | 2013 |
QVA149 versus glycopyrronium for COPD.
Topics: Female; Glycopyrrolate; Humans; Indans; Male; Pulmonary Disease, Chronic Obstructive; Quinolones; Respiratory System; Scopolamine Derivatives | 2013 |
QVA149 versus glycopyrronium for COPD - authors' reply.
Topics: Female; Glycopyrrolate; Humans; Indans; Male; Pulmonary Disease, Chronic Obstructive; Quinolones; Respiratory System; Scopolamine Derivatives | 2013 |
Long-acting bronchodilators in COPD: an evolving story.
Topics: Bronchodilator Agents; Female; Humans; Indans; Male; Pulmonary Disease, Chronic Obstructive; Quinolones; Scopolamine Derivatives; Tiotropium Bromide | 2013 |
Efficacy of indacaterol on quality of life and pulmonary function in patients with COPD and inhaler device preferences.
Topics: Administration, Inhalation; Adrenergic beta-2 Receptor Agonists; Aged; Aged, 80 and over; Bronchodilator Agents; Drug Therapy, Combination; Equipment Design; Female; Forced Expiratory Volume; Humans; Indans; Lung; Male; Muscarinic Antagonists; Nebulizers and Vaporizers; Patient Preference; Pulmonary Disease, Chronic Obstructive; Quality of Life; Quinolones; Recovery of Function; Severity of Illness Index; Surveys and Questionnaires; Time Factors; Treatment Outcome; Vital Capacity | 2014 |
The in vitro pharmacology of GS-5759, a novel bifunctional phosphodiesterase 4 inhibitor and long acting β2-adrenoceptor agonist.
Topics: Adrenergic beta-2 Receptor Agonists; Animals; Cell Culture Techniques; Cytokines; Fibroblasts; Guinea Pigs; Humans; Leukocytes, Mononuclear; Lipopolysaccharides; Male; Molecular Structure; Muscle, Smooth; Phosphodiesterase 4 Inhibitors; Pulmonary Disease, Chronic Obstructive; Quinolones; Respiratory System; Sulfones; Time Factors | 2014 |
The beta-2-adrenoreceptor agonists, formoterol and indacaterol, but not salbutamol, effectively suppress the reactivity of human neutrophils in vitro.
Topics: Adrenergic beta-2 Receptor Antagonists; Albuterol; Calcium; Cell Survival; Cyclic AMP; Cytosol; Ethanolamines; Flow Cytometry; Formoterol Fumarate; Humans; Indans; Leukotriene B4; Neutrophils; Oxygen Consumption; Pancreatic Elastase; Pulmonary Disease, Chronic Obstructive; Quinolones; Reactive Oxygen Species | 2014 |
Discovery of TD-4306, a long-acting β2-agonist for the treatment of asthma and COPD.
Topics: Adrenergic beta-2 Receptor Agonists; Animals; Asthma; Cell Line; Diphenylamine; Disease Models, Animal; Dogs; Dose-Response Relationship, Drug; Drug Discovery; Guinea Pigs; Humans; Molecular Structure; Pulmonary Disease, Chronic Obstructive; Quinolones; Rats; Receptors, Adrenergic, beta-2; Structure-Activity Relationship | 2014 |
Impact of multiple-dose versus single-dose inhaler devices on COPD patients' persistence with long-acting β₂-agonists: a dispensing database analysis.
Topics: Adrenergic beta-2 Receptor Agonists; Aged; Albuterol; Cohort Studies; Databases, Factual; Ethanolamines; Female; Formoterol Fumarate; Humans; Indans; Male; Metered Dose Inhalers; Pulmonary Disease, Chronic Obstructive; Quinolones; Retrospective Studies; Salmeterol Xinafoate | 2014 |
Indacaterol for the treatment of chronic obstructive pulmonary disease.
Topics: Administration, Inhalation; Adrenergic beta-2 Receptor Agonists; Bronchodilator Agents; Drug Administration Schedule; Drug Combinations; Glycopyrrolate; Humans; Indans; Pulmonary Disease, Chronic Obstructive; Quality of Life; Quinolones; Scopolamine Derivatives; Tiotropium Bromide; Treatment Outcome | 2015 |
What to use INSTEAD of inhaled corticosteroids in COPD?
Topics: Albuterol; Androstadienes; Bronchodilator Agents; Female; Glucocorticoids; Humans; Indans; Male; Pulmonary Disease, Chronic Obstructive; Quinolones | 2014 |
Systematic review comparing LABA, olodaterol, and indacaterol: limitations.
Topics: Adrenergic beta-2 Receptor Agonists; Benzoxazines; Bronchodilator Agents; Humans; Indans; Lung; Pulmonary Disease, Chronic Obstructive; Quinolones | 2014 |
Bronchodilating drugs for chronic obstructive pulmonary disease: current status and future trends.
Topics: Administration, Inhalation; Adrenergic beta-2 Receptor Agonists; Benzyl Alcohols; Bronchodilator Agents; Chlorobenzenes; Humans; Indans; Muscarinic Antagonists; Pulmonary Disease, Chronic Obstructive; Quinolones; Scopolamine Derivatives; Structure-Activity Relationship; Tiotropium Bromide | 2015 |
Discovery of (R)-1-(3-((2-chloro-4-(((2-hydroxy-2-(8-hydroxy-2-oxo-1,2-dihydroquinolin-5-yl)ethyl)amino)methyl)-5-methoxyphenyl)amino)-3-oxopropyl)piperidin-4-yl [1,1'-biphenyl]-2-ylcarbamate (TD-5959, GSK961081, batefenterol): first-in-class dual pharmac
Topics: Administration, Inhalation; Adrenergic beta-2 Receptor Agonists; Animals; Carbamates; CHO Cells; Cricetulus; Drug Discovery; Guinea Pigs; HEK293 Cells; Humans; Lung; Models, Molecular; Muscarinic Antagonists; Pulmonary Disease, Chronic Obstructive; Quinolones | 2015 |
Author's reply: To PMID 25114521.
Topics: Adrenergic beta-2 Receptor Agonists; Benzoxazines; Bronchodilator Agents; Humans; Indans; Lung; Pulmonary Disease, Chronic Obstructive; Quinolones | 2014 |
Cardiovascular safety of two bronchodilators' fixed-dose combination: indacaterol and glycopyrronium.
Topics: Adjuvants, Anesthesia; Administration, Inhalation; Bronchodilator Agents; Cardiovascular System; Clinical Trials as Topic; Drug Combinations; Glycopyrrolate; Humans; Indans; Pulmonary Disease, Chronic Obstructive; Quinolones | 2015 |
Salmeterol/fluticasone combination instead of indacaterol or vice-versa?
Topics: Albuterol; Androstadienes; Bronchodilator Agents; Female; Glucocorticoids; Humans; Indans; Male; Pulmonary Disease, Chronic Obstructive; Quinolones | 2015 |
Salmeterol/fluticasone combination instead of indacaterol or vice-versa?
Topics: Albuterol; Androstadienes; Bronchodilator Agents; Female; Glucocorticoids; Humans; Indans; Male; Pulmonary Disease, Chronic Obstructive; Quinolones | 2015 |
Efficacy of indacaterol as a single therapy versus salmeterol/fluticasone therapy in patients with milder chronic obstructive pulmonary disease.
Topics: Albuterol; Androstadienes; Bronchodilator Agents; Female; Glucocorticoids; Humans; Indans; Male; Pulmonary Disease, Chronic Obstructive; Quinolones | 2015 |
A real-world evaluation of indacaterol and other bronchodilators in COPD: the INFLOW study.
Topics: Administration, Inhalation; Adult; Africa; Aged; Asia; Bronchodilator Agents; Delayed-Action Preparations; Drug Monitoring; Drug Therapy, Combination; Female; Humans; Indans; Male; Middle Aged; Prospective Studies; Pulmonary Disease, Chronic Obstructive; Quinolones; Tiotropium Bromide; Treatment Outcome | 2015 |
Low Doses of Long-Acting β-Agonists/Long-Acting Muscarinic Agents with Large Effects. The FLIGHT Study.
Topics: Female; Glycopyrrolate; Humans; Indans; Male; Pulmonary Disease, Chronic Obstructive; Quinolones | 2015 |
Respiratory medications.
Topics: Administration, Inhalation; Aminopyridines; Androstadienes; Asthma; Beclomethasone; Benzamides; Cyclopropanes; Humans; Indans; Maleates; Nasal Sprays; Powders; Pulmonary Disease, Chronic Obstructive; Quinolones; Respiratory Tract Diseases; Rhinitis, Allergic | 2016 |
[ICS not indicated in the early stage].
Topics: Adrenergic beta-2 Receptor Agonists; Asthma; Bronchodilator Agents; Delayed-Action Preparations; Double-Blind Method; Drug Therapy, Combination; Fluticasone; Humans; Indans; Nebulizers and Vaporizers; Pulmonary Disease, Chronic Obstructive; Quinolones; Salmeterol Xinafoate | 2015 |
[Good bronchial dilatation helps keep patients physically active].
Topics: Bronchodilator Agents; Clinical Trials as Topic; Drug Combinations; Glycopyrrolate; Humans; Indans; Motor Activity; Nebulizers and Vaporizers; Pulmonary Disease, Chronic Obstructive; Quinolones | 2016 |
A cross-sectional study to assess inhalation device handling and patient satisfaction in COPD.
Topics: Administration, Inhalation; Aged; Bronchodilator Agents; Cross-Sectional Studies; Equipment Design; Female; Humans; Indans; Male; Middle Aged; Nebulizers and Vaporizers; Patient Preference; Pulmonary Disease, Chronic Obstructive; Quinolones; Spain; Surveys and Questionnaires; Tiotropium Bromide | 2016 |
Seebri Neohaler and Utibron Neohaler for COPD.
Topics: Administration, Inhalation; Adrenergic beta-2 Receptor Agonists; Bronchodilator Agents; Drug Administration Schedule; Drug Combinations; Drug Interactions; Female; Glycopyrrolate; Humans; Indans; Lung; Male; Muscarinic Antagonists; Nebulizers and Vaporizers; Pregnancy; Pulmonary Disease, Chronic Obstructive; Quinolones; Risk Factors; Treatment Outcome | 2016 |
Population pharmacokinetics of IND/GLY (indacaterol/glycopyrronium) in COPD patients.
Topics: Adult; Aged; Aged, 80 and over; Bronchodilator Agents; Drug Combinations; Female; Glycopyrrolate; Humans; Indans; Male; Middle Aged; Models, Biological; Pulmonary Disease, Chronic Obstructive; Quinolones | 2016 |
[Narrowing indications for inhaled steroids in COPD].
Topics: Bronchodilator Agents; Clinical Trials as Topic; Disease Progression; Drug Combinations; Glycopyrrolate; Humans; Indans; Nebulizers and Vaporizers; Pulmonary Disease, Chronic Obstructive; Quinolones | 2016 |
[UBC internal medicine returns to the respiratory tract area].
Topics: Bronchodilator Agents; Drug Combinations; Glycopyrrolate; Humans; Indans; Nebulizers and Vaporizers; Pulmonary Disease, Chronic Obstructive; Quinolones | 2016 |
Another Choice for Prevention of COPD Exacerbations.
Topics: Adrenergic beta-2 Receptor Agonists; Female; Fluticasone-Salmeterol Drug Combination; Glucocorticoids; Glycopyrrolate; Humans; Indans; Male; Muscarinic Antagonists; Pulmonary Disease, Chronic Obstructive; Quinolones | 2016 |
Cost Effectiveness of the Long-Acting β2-Adrenergic Agonist (LABA)/Long-Acting Muscarinic Antagonist Dual Bronchodilator Indacaterol/Glycopyrronium Versus the LABA/Inhaled Corticosteroid Combination Salmeterol/Fluticasone in Patients with Chronic Obstruct
Topics: Administration, Inhalation; Aged; Bronchodilator Agents; Canada; Cost-Benefit Analysis; Drug Costs; Drug Therapy, Combination; Fluticasone; France; Glycopyrrolate; Health Care Costs; Humans; Indans; Italy; Male; Portugal; Pulmonary Disease, Chronic Obstructive; Quinolones; Salmeterol Xinafoate | 2016 |
Indacaterol-Glycopyrronium for COPD.
Topics: Bronchodilator Agents; Forced Expiratory Volume; Glycopyrrolate; Humans; Indans; Muscarinic Antagonists; Pulmonary Disease, Chronic Obstructive; Quinolones; Treatment Outcome | 2016 |
Indacaterol-Glycopyrronium for COPD.
Topics: Bronchodilator Agents; Forced Expiratory Volume; Glycopyrrolate; Humans; Indans; Muscarinic Antagonists; Pulmonary Disease, Chronic Obstructive; Quinolones; Treatment Outcome | 2016 |
Indacaterol-Glycopyrronium for COPD.
Topics: Bronchodilator Agents; Forced Expiratory Volume; Glycopyrrolate; Humans; Indans; Muscarinic Antagonists; Pulmonary Disease, Chronic Obstructive; Quinolones; Treatment Outcome | 2016 |
Indacaterol-Glycopyrronium for COPD.
Topics: Bronchodilator Agents; Forced Expiratory Volume; Glycopyrrolate; Humans; Indans; Muscarinic Antagonists; Pulmonary Disease, Chronic Obstructive; Quinolones; Treatment Outcome | 2016 |
Indacaterol/glycopyrronium in symptomatic patients with COPD (GOLD B and GOLD D) versus salmeterol/fluticasone: ILLUMINATE/LANTERN pooled analysis.
Topics: Adrenergic beta-2 Receptor Agonists; Aged; Bronchodilator Agents; Clinical Trials, Phase III as Topic; Female; Fluticasone-Salmeterol Drug Combination; Forced Expiratory Volume; Glycopyrrolate; Humans; Indans; Lung; Male; Middle Aged; Muscarinic Antagonists; Pulmonary Disease, Chronic Obstructive; Quinolones; Randomized Controlled Trials as Topic; Recovery of Function; Severity of Illness Index; Spirometry; Surveys and Questionnaires; Time Factors; Treatment Outcome; Vital Capacity | 2016 |
Combination of glycopyrronium and indacaterol inhibits carbachol-induced ERK5 signal in fibrotic processes.
Topics: Adrenergic beta-2 Receptor Antagonists; Aged; Carbachol; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Glycopyrrolate; Humans; Indans; Male; Middle Aged; Mitogen-Activated Protein Kinase 7; Muscarinic Antagonists; Pulmonary Disease, Chronic Obstructive; Pulmonary Fibrosis; Quinolones; Signal Transduction; Treatment Outcome | 2017 |
New options for bronchodilator treatment in COPD.
Topics: Adrenergic beta-Agonists; Bronchodilator Agents; Drug Therapy, Combination; Forced Expiratory Volume; Humans; Indans; Pulmonary Disease, Chronic Obstructive; Quinolones | 2010 |
Characteristics of a capsule based dry powder inhaler for the delivery of indacaterol.
Topics: Adrenergic beta-2 Receptor Agonists; Aged; Aged, 80 and over; Dry Powder Inhalers; Female; Humans; Indans; Male; Middle Aged; Netherlands; Patient Compliance; Pulmonary Disease, Chronic Obstructive; Quinolones; Severity of Illness Index | 2010 |
Cardio- and cerebrovascular safety of indacaterol vs formoterol, salmeterol, tiotropium and placebo in COPD.
Topics: Adult; Albuterol; Bronchodilator Agents; Cardiovascular Diseases; Cerebrovascular Disorders; Ethanolamines; Female; Forced Expiratory Volume; Formoterol Fumarate; Humans; Indans; Male; Middle Aged; Placebos; Pulmonary Disease, Chronic Obstructive; Quinolones; Risk Factors; Salmeterol Xinafoate; Scopolamine Derivatives; Smoking; Tiotropium Bromide | 2011 |
Safety, tolerability and pharmacokinetics of single escalating doses of indacaterol, a once-daily beta2-agonist bronchodilator, in subjects with COPD.
Topics: Adrenergic beta-2 Receptor Agonists; Adult; Aged; Area Under Curve; Bronchodilator Agents; Drug Administration Schedule; Female; Humans; Indans; Male; Middle Aged; Pulmonary Disease, Chronic Obstructive; Quinolones | 2011 |
Indacaterol: pharmacologic profile, efficacy and safety in the treatment of adults with COPD.
Topics: Adrenal Cortex Hormones; Adrenergic beta-Agonists; Cholinergic Antagonists; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Humans; Indans; Pulmonary Disease, Chronic Obstructive; Quinolones; Treatment Outcome | 2011 |
[Pulmonary medicine. Two new drugs for the treatment of COPD].
Topics: Aminopyridines; Anti-Inflammatory Agents; Benzamides; Bronchodilator Agents; Cyclopropanes; Humans; Indans; Pulmonary Disease, Chronic Obstructive; Quinolones | 2011 |
[New drugs in chronic obstructive pulmonary disease].
Topics: Aminopyridines; Benzamides; Bronchodilator Agents; Cyclopropanes; Drug Therapy, Combination; Humans; Indans; Pulmonary Disease, Chronic Obstructive; Quinolones; Treatment Outcome | 2011 |
[Novel controllers of airway obstruction in COPD patients].
Topics: Airway Obstruction; Amphetamines; Bronchodilator Agents; Drug Administration Schedule; Drug Combinations; Humans; Hydroxyquinolines; Indans; Muscarinic Antagonists; Patient Compliance; Pulmonary Disease, Chronic Obstructive; Quinolones | 2011 |
Cost-utility analysis of indacaterol in Germany: a once-daily maintenance bronchodilator for patients with COPD.
Topics: Albuterol; Bronchodilator Agents; Cost-Benefit Analysis; Female; Forced Expiratory Volume; Germany; Humans; Indans; Male; Markov Chains; Middle Aged; Pulmonary Disease, Chronic Obstructive; Quinolones; Salmeterol Xinafoate; Scopolamine Derivatives; Survival Analysis; Tiotropium Bromide; Treatment Outcome | 2011 |
Indacaterol.
Topics: Adrenergic beta-2 Receptor Agonists; Humans; Indans; Inspiratory Capacity; Pulmonary Disease, Chronic Obstructive; Quinolones | 2011 |
[Medication of the month. Indacaterol (Onbrez Breezhaler) and chronic obstructive pulmonary disease].
Topics: Adrenergic beta-2 Receptor Agonists; Humans; Indans; Pulmonary Disease, Chronic Obstructive; Quinolones | 2011 |
The risks and benefits of indacaterol--the FDA's review.
Topics: Administration, Inhalation; Adrenergic beta-2 Receptor Antagonists; Asthma; Dose-Response Relationship, Drug; Drug Approval; Drug Evaluation; Humans; Indans; Pulmonary Disease, Chronic Obstructive; Quinolones; United States; United States Food and Drug Administration | 2011 |
[Indacaterol (Onbrez Breezhaler), oral inhalation].
Topics: Adrenergic beta-2 Receptor Agonists; Bronchodilator Agents; Drug Interactions; Humans; Indans; Nebulizers and Vaporizers; Pulmonary Disease, Chronic Obstructive; Quinolones | 2011 |
Spirometric inclusion criteria of COPD patients in randomized clinical trials.
Topics: Bronchodilator Agents; Female; Humans; Indans; Male; Pulmonary Disease, Chronic Obstructive; Quinolones; Scopolamine Derivatives; Vital Capacity | 2012 |
Indacaterol: a new long-acting β2-agonist in the management of chronic obstructive pulmonary disease.
Topics: Adrenergic beta-Agonists; Clinical Trials as Topic; Drug Approval; Humans; Indans; Pulmonary Disease, Chronic Obstructive; Quinolones; Respiratory Function Tests; United States; United States Food and Drug Administration | 2012 |
Indacterol (Arcapta Neohaler) for COPD.
Topics: Administration, Inhalation; Adrenergic beta-2 Receptor Agonists; Humans; Indans; Pulmonary Disease, Chronic Obstructive; Quinolones | 2012 |
▾Indacaterol for COPD.
Topics: Administration, Inhalation; Adrenergic beta-2 Receptor Agonists; Bronchodilator Agents; Cough; Dose-Response Relationship, Drug; Forced Expiratory Volume; Humans; Indans; Practice Guidelines as Topic; Pulmonary Disease, Chronic Obstructive; Quinolones; Randomized Controlled Trials as Topic; Respiratory Function Tests; Severity of Illness Index; United Kingdom | 2012 |
Efficacy of once-daily indacaterol relative to alternative bronchodilators in COPD: a patient-level mixed treatment comparison.
Topics: Bayes Theorem; Bronchodilator Agents; Endpoint Determination; Female; Humans; Indans; Male; Middle Aged; Pulmonary Disease, Chronic Obstructive; Quinolones; Randomized Controlled Trials as Topic; Surveys and Questionnaires; Treatment Outcome | 2012 |
Extension of three-arm non-inferiority studies to trials with multiple new treatments.
Topics: Algorithms; Bronchodilator Agents; Clinical Trials as Topic; Humans; Indans; Pulmonary Disease, Chronic Obstructive; Quinolones; Sample Size; Scopolamine Derivatives; Spirometry; Tiotropium Bromide | 2012 |
Association between antibiotic treatment and outcomes in patients hospitalized with acute exacerbation of COPD treated with systemic steroids.
Topics: Aged; Anti-Bacterial Agents; Cephalosporins; Cohort Studies; Disease Progression; Drug Therapy, Combination; Female; Glucocorticoids; Hospital Mortality; Humans; Macrolides; Male; Middle Aged; Multivariate Analysis; Patient Readmission; Pulmonary Disease, Chronic Obstructive; Quinolones; Retrospective Studies; Treatment Outcome | 2013 |
Model-based drug approval - the rubber hits the road.
Topics: Adrenergic beta-2 Receptor Agonists; Bronchodilator Agents; Drug Discovery; Drug Dosage Calculations; Humans; Indans; Lung; Models, Theoretical; Pulmonary Disease, Chronic Obstructive; Quinolones | 2012 |
Comment on the report "limitations of model-based dose selection for indacaterol in patients with chronic obstructive pulmonary disease".
Topics: Adrenergic beta-2 Receptor Agonists; Bronchodilator Agents; Drug Discovery; Drug Dosage Calculations; Humans; Indans; Lung; Models, Theoretical; Pulmonary Disease, Chronic Obstructive; Quinolones | 2012 |
A step forward in COPD management: reading between the lines.
Topics: Adrenergic beta-Agonists; Bronchodilator Agents; Humans; Indans; Pulmonary Disease, Chronic Obstructive; Quinolones; Scopolamine Derivatives; Tiotropium Bromide | 2012 |
Indacaterol Novartis/skyePharma.
Topics: Administration, Inhalation; Adrenergic beta-Agonists; Animals; Asthma; Bronchodilator Agents; Drug Evaluation, Preclinical; Humans; Indans; Patents as Topic; Pulmonary Disease, Chronic Obstructive; Quinolones; Randomized Controlled Trials as Topic | 2006 |
Vulnerability of gastric mucosa to prednisolone in rats chronically exposed to cigarette smoke.
Topics: Alanine; Animals; Anti-Ulcer Agents; Blood Gas Analysis; Dinoprostone; Disease Models, Animal; Gastric Mucosa; Hypoxia-Inducible Factor 1, alpha Subunit; Lipid Peroxides; Male; Peptic Ulcer Hemorrhage; Prednisolone; Pulmonary Disease, Chronic Obstructive; Quinolones; Rats; Rats, Wistar; Respiratory Function Tests; Respiratory System; Smoking; Stomach Ulcer; Vascular Endothelial Growth Factor A | 2008 |
Pulmonary disposition of lomefloxacin in patients with acute exacerbation of chronic obstructive pulmonary disease. A multiple-dose study.
Topics: Administration, Oral; Anti-Infective Agents; Antitubercular Agents; Bronchi; Bronchoalveolar Lavage Fluid; Fluoroquinolones; Humans; Lung; Microbial Sensitivity Tests; Pulmonary Disease, Chronic Obstructive; Quinolones | 2001 |
Safety and effectiveness of lomefloxacin in patients with acute exacerbation of chronic bronchitis (AECB) chronically treated with oral theophyllines.
Topics: Acute Disease; Administration, Oral; Adult; Aged; Anti-Infective Agents; Bronchitis; Cross-Sectional Studies; Female; Fluoroquinolones; Humans; Male; Middle Aged; Pulmonary Disease, Chronic Obstructive; Quinolones; Theophylline | 2001 |